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 ABSTRACT 
 
Epigenetic alterations are common in cancer. One example is aberrant 
hypermethylation of the promoters of tumor suppressor genes and hence silencing of 
gene expression. Azacitidine, a DNA hypomethylating drug, has been shown to 
prolong survival in patients with high-risk myelodysplastic syndromes (MDS) compared 
to conventional care regimens, and is now recommended as first-line therapy for 
patients not eligible for allogeneic stem cell transplantation. 
Azacitidine has DNA hypomethylating properties and has been shown to re-induce 
expression of aberrantly silenced genes in various cell lines. However, its mechanism 
of action in primary hematopoietic progenitors in vivo is relatively unknown. 
This thesis aimed to assess the prognostic value of DNA methylation in high-risk MDS 
and in de novo acute myeloid leukemia (AML), to evaluate the effect and feasibility of 
maintenance treatment with azacitidine in patients in complete remission (CR) after 
induction chemotherapy, and to study mechanisms of action of azacitidine in primary 
MDS and normal bone marrow (NBM) progenitors. 
We show, for the first time, a correlation between promoter methylation patterns and 
outcome of induction chemotherapy in a cohort of 60 patients with high-risk MDS or 
AML following MDS (MDS-AML). Patients who were hypermethylated in the E-
cadherin (CDH) promoter had lower CR rates than those without methylation 
(P=0.008). CDH methylation was also associated with shorter survival (P=0.003).  
By contrast, in a material of 107 patients with de novo AML CDH methylation had no 
impact on survival or on outcome of induction chemotherapy. In fact, promoter 
hypermethylation of P15ink4b, previously reported as a poor prognostic marker in MDS 
and MDS-AML, as well as genome wide promoter methylation corresponded to a 
better survival (P=0.001 and 0.005, respectively). Another novel finding was that de 
novo AML patients with a low degree of global DNA methylation had a poorer 
response to induction chemotherapy (P=0.005). These differences in the prognostic 
value of methylation status in MDS/MDS-AML and de novo AML suggest important 
differences in disease biology and response to treatment between the two entities.  
Several mechanisms of action for azacitidine have been suggested, including induction 
of apoptosis, differentiation of blasts, histone modification, immunomodulation and 
DNA and RNA demethylation. However, the majority of data results from cell line 
experiments or from sequential bone marrow sampling during azacitidine treatment. In 
paper IV of this thesis we exposed primary MDS and normal bone marrow (NBM) 
progenitors to azacitidine in vitro. Interestingly, azacytidine caused marked up-
regulation of gene expression in MDS but not in NBM CD34+ marrow cells. Compared 
to cell line experiments, induction of apoptosis as well as global and gene-specific 
hypomethylation was less pronounced in primary cells. Interestingly, azacitidine in 
doses up to 5 µM had no negative effect on proliferation in suspension cultures, and 
doses up to 0.5 µM even had a positive effect on colony growth. This is a useful finding 
since it may support the use of the drug for patients with low-risk MDS, and as 
maintenance after allogeneic stem cell transplantation.  
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 1 LIST OF ABBREVIATIONS 
 
 
AML Acute myeloid leukemia 
APL Acute promyelocytic leukemia 
ATRA All-trans retinoic acid 
CCR Conventional care regimens 
CDH E-cadherin 
CDR Commonly deleted region 
CMML Chronic myelomonocytic leukemia 
CR Complete remission 
CRi Complete remission with insufficient hematologica recovery 
DFS Disease free survival 
DGGE Denaturing gradient gel electrophoresis 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
EMEA European Medicines Agency 
EPO Erythropoietin 
FAB Frensh-British- American classification 
FDA Food and Drug Administration 
FISH Fluorescence in situ hybridization 
G-CSF Granulocyte colony-stimulating factor 
HAT Histone acteyltransferase 
HDAC Histone deacetylase 
HIC Hypermethylated in Cancer 1 
IPSS International prognostic scoring system 
MDS- AML AML following a previous episode of MDS 
MDS Myelodysplastic syndromes 
MNC Mononuclear cells 
MPN Myeloproliferative neoplasms 
NBM Normal bone marrow 
OS Overall survival 
P15 P15ink4b/CDKN2b 
PCR Polymerase chain reaction 
RA Refractory anemia 
RAEB Refractory anemia with excess blasts 
RAEB-t Refractory anemia with excess blasts in transformation 
RARS Refractory anemia with ring sideroblasts 
RCMD Refractory cytopenia with multilineage dysplasia 
RNA Ribonucleic acid 
s.c. Subcutaneous 
WBC White blood cells 
WHO World Health Organization 
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 2 INTRODUCTION 
 
2.1 Myelodysplatic syndrome (MDS) 
 
2.1.1 General background and epidemiology 
 
Myelodysplastic syndromes (MDS) 
constitutes a heterogeneous group of 
clonal malignant bone marrow 
diseases. The incidence of MDS varies 
between 4-10/100 000/year in different 
materials, and increases with age 
(Figure 1).1-5 MDS is mainly a disease 
of the elderly. Median age at diagnosis 
is around 75 years with a slight male 
predominance.1-5 Ninety percent of 
MDS cases are idiopathic (de novo 
MDS), while around 10% are defined as 
therapy-related MDS, e.g. arising as a 
result from previous exposure to 
cytotoxic drugs or radiotherapy.6-8 Some 
studies have suggested an association 
between MDS and e.g. benzene, 
ionizing radiation, smoking and 
pesticides but results are inconsistent 
between studies.9-11 Although familial 
cases have been reported, and MDS 
definitely is associated to congenital 
disorders such as Fanconi’s anemia, 
MDS is in most cases not a hereditary 
disease.12 
 
 
 
Figure 1: The yearly incidence (per 100.000 individuals) of MDS according to age-      
groups and gender (Germing et al, Haematologica 2004)5 
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 2.1.2 Clinical presentation 
 
The clinical presentation and the natural 
course of MDS vary largely among 
diagnostic subgroups and between 
individuals. An increasing number of 
patients are diagnosed though routine 
blood samples obtained when the 
patient consults their physician for non-
MDS related problems. Symptoms from 
MDS are often secondary to the 
peripheral cytopenias caused by bone 
marrow failure. At diagnosis, a majority 
of the patients have some degree of 
anemia, which is usually macrocytic. 
Around 55% present with hemoglobin 
value <100 g/l.13 Anemia-related 
symptoms (e.g. fatigue, dyspnea, 
worsening of angina pectoris and heart 
failure) constitute the most common 
clinical presentation of MDS. Other 
frequent symptoms include bleedings 
due to thrombocytopenia and platelet 
dysfunction, as well as infectious 
complications due to neutropenia. 
Bleeding and infection are also the 
major causes of death in MDS14-17 Less 
common MDS-related symptoms 
include autoimmune diseases such as 
autoimmune hemolytic anemia and 
arthitis.18,19 Around one third of patients 
eventually develop acute myeloid 
leukemia (AML), so-called MDS-AML.13 
 
2.1.3 Bone marrow morphology and cytogenetics 
 
The bone marrow of MDS patients is 
typically hypercellular. According to the 
WHO classification, at least 10% of the 
progenitors of one of the erythroid, 
myeloid and megakaryocytic lineage 
must show significant dysplasia for a 
diagnosis of MDS. Dysplasia is then 
graded into unilineage (one lineage) 
and multilineage (≥two lineages). 
Examples of dysplasia include nuclear 
abnormalities, poor granulation of the 
cytoplasm of granulocytes or ringed 
sideroblasts. The percentage of blast 
cells in bone marrow smears influences 
the classification of MDS and is 
achieved from counting at least 400 
nucleated cells.20 Around 50% of 
patients with MDS present one or more 
chromosomal aberrations. The most 
frequent finding is deletion of 5q 
(del5q), which alone or in combination, 
is found in close to 30% of the 
abnormal cases.21 Genetic aberrations 
in MDS typically involve unbalanced 
loss or gain of genetic material (del5q, -
7, +8 etc) but there are no MDS-specific 
abnormalities.13,21 In secondary MDS, 
the type of cytogenetic aberrations are 
somewhat different and with a higher 
incidence of complex karyotypes, 
defined as ≥3 abnormalities.22
 
2.1.4 Pathogenesis 
 
Since Knudson introduced his famous 
two-hit hypothesis in the early 70’s, the 
accumulation of multiple genetic events 
has been considered necessary for a 
normal cell to transform into a cancer 
cell.23 This multi-step theory is most 
likely valid also for MDS. Considering 
the heterogeneous nature of the 
disease, it is unlikely that a few genetic 
aberrations would explain the clinical 
picture for the whole group.  
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 A few cytogenetic aberrations are 
recurring in MDS (e.g. del(5q), del(7q), 
del(20q), monosomy 5 and 7, and 
trisomy 8).21 However, no aberration is 
pathognomonic for MDS and none of 
them is probably sufficient for the 
development of the disease. The genes 
involved in these aberrations are still 
basically unknown, with one exception;  
the deletion on chromosome 5q31 
associated with low-risk MDS with 
del(5q) has been extensively studied. 
The genes proposed as putative 
candidates for the pathogenesis of the 
5q- syndrome include SPARC and 
RPS14 (see below 2.1.7.5). Since the 
remaining allele is not mutated in 
del(5q) MDS, haploinsufficiency has 
been suggested as a possible 
mechanism. The impact of point 
mutations is less well studied in MDS 
than in de novo AML. Frequent 
mutations that are strongly associated 
with prognosis in de novo AML (e.g. 
NPM1, FLT-3 and MLL), are rarely 
found in MDS at diagnosis, but may 
appear at disease progression.24-28 
Their prognostic value in MDS is, 
however, less well defined. JAK-2 
mutations, a hallmark of myelo-
proliferative diseases leading to 
constitutive thyrosine phosphorylation 
activity, can be found in subgroups of 
MDS patients typically presenting with 
elevated platelets, RARS-T (WHO 
mixed MDS/MPN) and occasionally in 
the 5q- syndrome.20,29-32  
 
Epigenetic changes, i.e. heritable 
changes in gene expression without 
alteration in the DNA sequence, are a 
common feature of the cancer cell. Its 
role in MDS is discussed in detail below 
(see 2.3.2). 
 
Several studies have showed increased 
apoptosis (programmed cell death, see 
below 2.4), of hematopoietic 
progenitors in the bone marrow of MDS 
patients.33 This explains the clinical 
picture in MDS with hypercellular bone 
marrow and peripheral cytopenia. It is, 
however, intriguing and a topic for 
ongoing research how a malignant 
clone with increased apoptosis can gain 
a growth advantage over normal cells. 
The exact mechanisms underlying 
increased apoptosis in MDS are unclear 
but seem to involve dysregulation of 
both the extrinsic pathway via death 
receptors (e.g. FAS and TNF-α) and the 
intrinsic apoptotic pathways (e.g. 
mitochondria and Bcl-2 family). Up-
regulation of death receptors as well as 
pro-apoptotic members of the Bcl-2 
family is seen in MDS.34-36 Erythroid 
progenitors in RARS patients show a 
spontaneous leakage of cytochrome c 
from the mitochondrial intermembrane 
space and subsequent activation of 
caspases.37 P53 is a pro-apoptotic 
protein and mutations in the TP53 gene 
are common in cancer and usually 
correlate to poor prognosis and poor 
response to treatment.38,39 In MDS 
TP53 mutations are seen in around 
10% of the patients and mainly in high-
risk disease and therapy-related 
cases.40,41 Also in MDS TP53 mutations 
relates to poor outcome and resistance 
to therapy.24,42,43 
   
In a subgroup of MDS patients (see 
2.1.7.4) the disease mechanism seems 
to be immune mediated, similar to that 
in aplastic anemia. MDS bone marrow 
precursors are in these cases the target 
of cytotoxic T-cells and natural killer 
(NK) cells. The hypothesis is supported 
by observations that therapeutic 
depletion of T-cells may improve colony 
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 growth from bone marrow mononuclear 
cells (MNC) in MDS patients, while not 
affecting normal bone marrow.45-47 
Moreover, several studies have 
reported on oligoclonal expansion of T-
lymphocytes in MDS.48-50 
 
The interaction between the bone 
marrow stroma and hematopoietic stem 
cells is crucial for the survival and the 
function of the stem cells. The 
interaction consists of both cell-to-cell 
adhesion and secretion of cytokines 
from the stromal cells.51 In MDS the 
stroma seems to have decreased ability 
to support normal hematopoietic stem 
cells.52
 
2.1.5 Classification 
 
The French-American-British (FAB) 
classification of MDS was presented in 
1982.53 It was based exclusively on 
bone marrow morphology and patients 
were classified into subgroups 
according to the amount of blasts in the 
bone marrow and the existence or not 
of ring sideroblasts. The WHO 
classification was first published in 2001 
and then updated in 2008.20 This is now 
the most widely used classification 
system for MDS. The number of 
dysplastic lineages is of importance.  
Patients with dysplasia in more than 
one lineage are due to their poorer 
prognosis separated from refractory 
anemia (RA) and refractory anemia with 
ring sideroblasts (RARS), and classified 
as refractory cytopenia with 
multilineage dysplasia (RCMD). 
Patients with a del(5q) as the sole 
cytogenetic aberration and marrow 
blasts <5% form a separate entity. The 
FAB-subgroup refractory anemia with 
excess of blasts in transformation 
(RAEB-t) disappeared in the WHO 
classification when the cut-off for bone 
marrow blasts for a diagnosis of AML 
was reduced from 30 to 20%. The 
reason was the similar prognosis and 
response to treatment between RAEB-t 
and AML. Chronic myelomonocytic 
leukemia (CMML) was transferred from 
the MDS classification to a new 
subgroup; mixed MDS/MPN. The full 
WHO classification of MDS is shown in 
Table 1. 
 
2.1.6 Prognosis 
 
Prognosis in MDS varies a lot. Some 
patients live for many years with only 
moderate anemia whereas others are 
transfusion dependent at diagnosis. 
The risk of leukemic transformation is 
very high in some patients and almost 
absent in some. Since 1997 the 
international prognostic scoring system 
(IPSS) has been the most widely used 
prognostic tool for patients with MDS, 
serving as a basis for therapeutic 
decisions.13 It is based on different risk 
groups derived from the number of 
cytopenias, percentage of bone marrow 
blasts and type of cytogenetic 
aberration. Patients are grouped into 
one of four prognostic groups; low, 
intermediate-1, intermediate-2 and high 
risk, with increasing risk of leukemic 
transformation and poorer survival. In 
studies, the low and intermediate-1 
subgroups are often referred to as low-
risk MDS and the intermediate-2 and 
high as high-risk disease. The IPSS is 
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 described in detail in Table 2. 
Furthermore, the WHO classification 
system, as well as transfusion 
dependency provides additional help in 
prognostication and is included into a 
new prognostic scoring system, the 
WPSS.54 Moderate to severe bone 
marrow fibrosis is also associated with 
significantly poorer prognosis.55 
 
 
Table 1: The 2008 WHO classification of myelodysplastic syndromes20 
 
Disease Blood findings Bone marrow findings 
Refractory cytopenias with 
Unilineage dysplasia (RCUD) 
Refractory anemia (RA) 
Refractory neutropenia (RN) 
Refractory thrombocytopenia (RT) 
Unicytopenia or bicytopeniaa 
No or rare blasts (<1%) 
 
Unilineage dysplasia; >10% of the cells 
of the affected lineage are dysplastic 
<5% blasts 
<15% of the erythroid precursors are ring 
sideroblasts 
Refractory anemia with ring sideroblasts 
(RARS) 
Anemia 
No blasts 
Erythroid dysplasia only 
<5% blasts 
≥15% of ring sideroblasts 
Refractory cytopenia with multilineage 
dysplasia (RCMD) 
Cytopenias 
No or rare blasts (<1%) 
No Auer rods 
<1x109 monocytes/L 
Dysplasia in >10% of the cells of two or 
more myeloid lineages 
<5% blasts 
No Auer rods 
± ring sideroblasts 
Refractory anemia with excess blasts-1 
(RAEB-1) 
Cytopenias 
<5% blasts 
No Auer rods 
<1x109 monocytes/L 
Unilineage or multilineage dysplasia 
5-9% blasts 
No Auer rods 
Refractory anemia with excess blasts-2 
(RAEB-2) 
Cytopenias 
5-19% blasts 
± Auer rodsb 
<1x109 monocytes/L 
Unilineage or multilineage dysplasia 
10-19% blasts 
± Auer rodsb
Myelodysplastic syndrome unclassified 
(MDS-U) 
Cytopenias 
No or rare blasts (<1%) 
No Auer rods 
Unequivocal dysplasia in <10% of cells in 
one or more myeloid lineages 
<5% blasts 
MDS associated with del(5q) Anemia 
No or rare blasts (<1%) 
Platelet count usually normal or 
increased 
Normal to increased number of 
megakaryocytes with hypolobated nuclei 
<5% blasts 
Isolated del(5q) cytogenetic abnormality 
No Auer rods 
a Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U b 
If the diagnostic critera for MDS are fulfilled and Auer rods are present, the patient should always be 
categorized as RAEB-2 
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 Table 2: The international prognostic scoring system13 
 
Prognostic 
variable 
0 points 0.5 points 1.0 point 1.5 points 
Number of 
cytopeniasa
0-1 1-2 - - 
Karyotypeb Good Intermediate Poor - 
Bone marrow 
blasts (%) 
<5 5-10 - 11-20 
Risk group Score Median survival 
(years) 
25% AML 
evolution 
(years) 
 
Low 0 5.7 9.4  
Intermediate-1 0.5-1.0 3.5 3.3  
Intermediate-2 1.5-2.0 1.2 1.1  
High ≥2.5 0.4 0.2  
a Cytopenias defined as hemoglobin <100 g/L, platelet counts <100 x 109/L and absolute neutrophil 
counts <1.8 x 109/L b Good: Normal, -Y, del(5q), del(20q); Poor: Complex karyotype (≥3 abnormalities) or 
chromosome 7 abnormalities; Intermediate: Not fulfilling criteria for good or poor.  
 
2.1.7 Treatment 
 
The clinical picture in MDS varies from 
mild, asymptomatic cytopenia to severe 
transfusion dependency and rapid 
leukemic transformation, and the 
expected survival times range from a 
few months to several years. A small 
subgroup of MDS has an almost normal 
life expectancy. Accordingly, therapy for 
the disease has to be individualized 
depending on symptoms, risk group, 
and age. Whereas some patients will 
not require any treatment, others will 
need intensive treatment with 
chemotherapy and also be eligible for 
allogeneic stem cell transplantation. 
 
2.1.7.1 Transfusion therapy 
 
A majority of patients with MDS will 
develop transfusion-dependent anemia 
at some time, and more than 50% have 
severe anemia already at diagnosis.13 
Hence, red blood cell transfusion is the 
most common therapy in MDS. Anemia 
is associated with increased morbidity 
and mortality, and with decreased 
quality of life, which improves with 
measures that increase the hemoglobin 
level.17,56-58 The hemoglobin target of 
transfusion therapy has to be adapted 
to the individual needs of each patient 
depending on symptoms and co-
morbidity. 
 
2.1.7.2 Iron chelation therapy 
 
All patients with a chronic need of red 
blood cell transfusions will eventually 
develop iron overload. In thalassemia 
major patients with severe and chronic 
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 transfusion dependency from early 
childhood, it is well known that iron 
overload will cause organ damage 
(liver, heart, pancreas) and eventually 
organ failure and death, and that 
treatment with iron chelators decreases 
both morbidity and mortality.59-61 
Excess iron is seen also in organs of 
heavily transfused MDS patients but 
there is still no clear evidence showing 
benefit of chelation therapy in MDS. A 
retrospective study shows that patients 
with higher ferritin levels have 
increased risk of death but whether this 
is due to the iron overload per se or just 
reflects a more severe disease is not 
clear.17 Improved erythropoiesis and 
reduced transfusion requirements have 
been reported after iron chelation 
therapy.62,63 Studies showing better 
survival in chelated patients are not 
prospective or randomized, and the 
results may reflect physicians 
inclination to avoid chelation therapy in 
patients expected to have poorer 
survival.64 One could argue that the 
effect might be different in individuals 
exposed to excess iron in a period 
when the organs are still growing 
(thalassemia) compared to those 
exposed adulthood (MDS patients). The 
recommendation for MDS, however, is 
to start iron chelation therapy 
(desferrioxamine, deferasirox or 
deferiprone) in MDS patients with an 
expected survival of more than 2 years 
after around 24 units of red blood cells 
or when serum ferritin reaches 1000-
2000 µg/L. A special subgroup that 
always should be considered for iron 
chelation is candidates for allogeneic 
stem cell transplantation.65-68 
2.1.7.3 Growth factors 
 
Several studies have shown improved 
erythropoiesis in MDS patients treated 
with subcutaneous (s.c.) injections of 
recombinant human erythropoietin 
(EPO) in doses between 30,000 and 
60,000 U/week. Meta-analyses show 
response rates between 16-82% 
depending on diagnostic subgroup.69.70 
Responses are rare in MDS with 
excess of blasts. RA patients respond 
better than patients with RARS and 
patients with unilineage dysplasia 
respond better than those with 
multilineage dysplasia.71 Addition of 
granulocyte colony-stimulating factor 
(G-CSF) significantly improves the 
erythroid response and is 
recommended for patients not 
responding to EPO alone and for 
transfusion-dependent RARS patients 
up-front.72-74 Response rates correlate 
with endogenous levels of serum-EPO 
and with the degree of transfusion 
need. These parameters are included 
into a predictive model for response 
developed by Hellström-Lindberg et al. 
(Table 3).75 A number of studies have 
shown improvement of quality of life by 
treating the anemia of MDS patients 
with EPO ± G-CSF.73-75 Several 
mechanisms of action have been 
suggested for growth factor therapy in 
MDS, e.g. inhibition of apoptosis in 
MDS progenitors, increased maturation 
of dysplastic blasts and stimulation of 
the remaining normal erythro-
poiesis.37,76,77
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 Table 3: Predictive model for response to EPO and G-CSF.75 
 
Variable Value Score 
Transfusion need <2 U 
≥2 U 
0 
1 
Serum EPO <500 U/L 
≥500 U/L 
0 
1 
Predictive group Score Response rate 
Good 0 74% 
Intermediate 1 23% 
Poor 2 7% 
  
 
2.1.7.4  Immunosuppression 
 
A small subgroup of patients with low-
risk MDS can benefit from immuno-
suppressive treatment with anti-
thymocyte globulin (ATG) ± cyclo-
sporine-A (CyA). Response rates are 
around 30% and the duration of 
response varies in different materials. 
Hypocellular bone marrow, age below 
60 years, and HLA DR15 positivity 
constitute positive predictive factors for 
response.78-81 
 
2.1.7.5 Immunomodulatory drugs 
 
Lenalidomide, an analogue to 
thalidomide, was approved by the US 
Food and Drug Administration (FDA) in 
2006 for the treatment of low-risk MDS 
with a karyotype including del(5q). The 
approval in the US was based on one 
study showing major erythroid response 
in 67%, and complete cytogenetic 
response in 45% of patients with low-
risk MDS and del(5q) with or without 
other abnomalities.82 However, the 
MDS hematopoietic stem cells seem to 
be resistant to treatment, as shown by a 
recent publication.83 In MDS patients 
without del(5q) the response rates are 
much lower; 26% major erythroid 
response and 19% complete 
cytogenetic response, and response 
durations are shorter.84 Response to 
lenalidomide is also observed in high-
risk MDS and AML with a karyotype 
including del(5q), but response rates 
are lower and treatment should more be 
seen as an induction regimen.85,86 The 
most common side effects of the drug 
are thrombocytopenia and neutropenia. 
Lenalidomide did not gain approval by 
the European Medicines Agency 
(EMEA) due to safety concerns based 
on reports of clonal evolution and 
higher rates of leukemic transformation 
than expected in patients who fail to 
achieve sustained remission.87,88 
Thalidomide induces few responses in 
MDS and cannot be recommended as 
treatment of the disease.89,90 The 
mechanisms of lenalidomide include 
anti-angiogenetic effects, effects on cell 
adhesion, modulation of T-cell immune 
response and induction of apoptosis in 
tumor cells.91 In vitro studies show that 
lenalidomide inhibits growth of MDS 
del(5q) progenitors but does not affect 
the growth of normal cells.92 
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 Haploinsufficiency of one or several 
genes expressed in the commonly 
deleted region (CDR) of MDS del(5q) 
has been postulated as a possible 
mechanism in del(5q). Restoration of 
gene expression levels could, 
accordingly, be a possible mode of 
action of lenalidomide. Several genes 
within the CDR have been investigated. 
The expression of SPARC, a gene 
coding for a protein with anti-
proliferative, anti-angiogenetic and anti-
adhesive effects, is down-regulated in 
del(5q) MDS progenitors and is up-
regulated by lenalidomide treatment.92 
Another gene of interest is RPS14, 
encoding for a component of the 40S 
ribosomal subunit. In vitro blocking of 
the gene in normal bone marrow 
progenitors by RNA interaction 
techniques led to impaired erythroid 
differentiation but preserved 
megakaryocytic differentiation, mimick-
ing the del(5q) syndrome. Increased 
expression of the gene in MDS cells by 
lentiviral techniques improved erythroid 
maturation.93 The gene is also up-
regulated by lenalidomide treatment.94 
 
2.1.7.6 Chemotherapy 
 
There is insufficient data for the 
recommendation of low dose 
chemotherapy such as e.g. 
hydroxyurea in MDS. In CMML-1, on 
the other hand, hydroxyurea  is the first-
line option to reduce high peripheral 
white blood cells (WBC).95 The use of 
low-dose (10-30 mg/m2/day s.c.) 
cytosine arabinoside (ara-C) induces 
response in around 30% of patients, but 
does not influence survival or leukemic 
transformation rate.96,97 Until the 
introduction of hypomethylating drugs 
(see below, 2.3.3.1) the only 
therapeutic option for patients with high-
risk MDS, not eligible for allogeneic 
hematopoietic stem cell transplantation, 
was induction chemotherapy, as used 
for AML. Around 50% of patients 
achieve complete remission (CR) with 
this therapy.98-102 Parameters indicating 
a more proliferative disease, such as 
high WBC and high lactate 
dehydrogenase (LDH), as well as 
complex karyotype correlates to lower 
probability for CR.98,101,102 However, CR 
durations are short, most often less 
than a year, and there is no evidence 
for cure from this treatment.98-100,102,103 
Conventional consolidation courses, 
autologous stem cell transplantation, 
interleukin-2 maintenance or G-CSF 
priming does not improve CR 
duration.99,100,102,104,105 Today, 
considering the positive survival data 
with hypomethylating agents, the 
rationale for induction chemotherapy is 
uncertain in patients where it cannot be 
followed by allogeneic stem cell 
transplantation. It might be considered 
in otherwise fit patients with high-risk 
disease and very rapidly increasing 
blasts, or after failure to hypo-
methylating drugs. 
 
2.1.7.7 Allogeneic stem cell transplantation 
 
As allogeneic transplantation of 
hematopoietic stem cells is the only 
potentially curative option in MDS, all 
newly diagnosed patients should be 
considered for this option.106 However, 
due to the high median age at diagnosis 
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 in MDS, only a minority of patients will 
be eligible. Allogeneic stem cell 
transplantation with conventional 
myeloablative conditioning regimens is 
usually only considered for patients up 
to about 60 years of age. Reduced 
intensity conditioning is tolerated even 
for older patients, but is also associated 
with a higher relapse rate.107 With 
myeloablative conditioning regimens 
overall survival (OS) is between 30-
50%, and relapse rates 20-40%.108-110 
Due to the high transplant related 
mortality in MDS (30-40%)108-110 the 
timing of transplant is of great 
importance. For patients with high-risk 
disease and thus short expected 
survival, allogeneic stem cell 
transplantation is recommended as a 
part of first-line treatment, usually 
following hypomethylating agents or 
induction chemotherapy. Decision-
making is much more difficult for 
patients with lower-risk disease, who 
may have a good quality life for several 
years with only supportive care and 
growth factors, but who eventually may 
die from disease. Patients that have 
achieved CR before transplantation 
have a much better outcome than those 
transplanted with resistant or relapsing 
disease.109,110   
 
2.1.7.8 Epigenetic therapies (see below: 2.3.3) 
 
2.2 Acute myeloid leukemia (AML) 
 
AML can either arise de novo, or 
secondary following a history of 
previous MDS, myeloproliferative 
neoplasms, or previous anti-cancer 
treatment with cytotoxic drugs or 
radiation therapy. The criteria for AML 
include ≥20% bone marrow blasts, and 
the occurrence of Auer rods is 
pathognomonic for the diagnosis. Table 
4 shows the classification of AML 
according to WHO.20 The incidence of 
AML is about 4/100,000/year with the 
majority of cases being de novo 
disease.111 With the exception of older 
patients with AML following MDS (MDS-
AML) and <30% bone marrow blasts, in 
whom the therapy of choice is 
hypomethylating drugs, and patients 
with AML FAB M3 (acute promyelocytic 
leukemia (APL)), a subgroup with 
particularly good prognosis and where 
all-trans retinoic acid (ATRA) should be 
added to the induction chemo.112 
Therapy for AML consists of induction 
chemotherapy followed by consolidation 
courses. Patients with high-risk disease 
and in some cases also those with 
intermediate risk, should, if possible, be 
subject to allogeneic stem cell 
transplantation already in first remission 
while the rest of patients are 
transplanted only after relapse and in 
second remission.113  
2.2.1 Differences between de novo AML and MDS-AML 
 
MDS-AML and de novo AML, apart 
from being two heterogeneous entities, 
show major differences. The median 
age is higher in MDS-AML than in de 
novo AML, and older MDS-AML 
patients tolerate intensive treatment 
less well. Prognosis is worse in MDS-
AML than in de novo AML.114 Among 
patients with de novo AML the rate of 
cytogenetic aberrations is comparable 
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 with MDS-AML, around 50%, but the 
type of aberrations differ. The typical 
aberration in de novo AML is a 
balanced translocation whereas in 
MDS-AML most commonly a loss of 
genetic material is seen. The same 
aberration can also have different 
prognostic value. A normal karyotype is 
e.g. associated with good prognosis in 
MDS, whereas in de novo AML it 
correlates to intermediate or poor 
prognosis depending on the co-
existence or not of molecular 
aberrations.24,115,116 The prognostic 
importance of genetic aberrations in de 
novo AML is shown in Table 5. 
 
Table 4: The 2008 WHO classification of acute myeloid leukemias20 
 
Disease Description 
AML with recurrent genetic 
abnormalities 
1. AML t(8;21)(q22;q22) RUNX1/RUNX1T1 
2. AML with inv(16)(p13;q22) or t(3;3)(p13;q22) CBFB-MYH11 
3. APL t(15;17)(q22;q21) PML-RARA 
4. AML with t(9;11)(p2;q23) MLLT3-MLL 
5. AML with t(6;9)(p23;q34) DDEK-NUP214 
6. AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2) RPN1-EVI1 
7. AML with t(1;22)(p13;13) RBM15-MKL1            
AML with myelodysplasia related 
changes 
Patients who have had a prior MDS or MPD that transforms to AML. 
AML and MDS, therapy related Patients that have had prior chemotherapy and/or radiation and that 
subsequently develop AML or MDS. 
AML not otherwise categorized Patients with AML that do not fall into any of the categories above. 
1. AML with minimal differentiation 
2. AML without maturation 
3. AML with maturation 
4. Acute myelomonocytic leukemia 
5. Acute monoblastic and monocytic leukemia 
6. Acute erythroid leukemia 
7. Acute megakaryoblastic leukemia 
8. Acute basophilic leukemia 
9. Acute panmyelosis with myelofibrosis 
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 Table 5: Genetic aberrations and prognosis in de novo AML116 
 
Risk group Type of genetic aberration 
Favorable APL with t(15;17)(q22;q12); PML-RARA 
inv(16)(p13.1;122) or t(16;16)(p13.1;q22); CBFB-MYH11 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
Normal karyotype and mutated NPM1 without FLT3-ITD 
Normal karyotype and mutated CEBPA 
Intermediate Normal karyotype and mutated NPM1 and FLT3-ITD 
Normal karyotype and wild-type NPM1 and FLT3-ITD 
Normal karyotype and wild-type NPM1 without FLT3-ITD 
t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic aberrations not classified as favorable or adverse 
Adverse inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34) DDEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; Abnl(17p); Complex karyotype 
 
 
 
2.3 Epigenetics and epigenetic therapies 
 
2.3.1 General background on epigenetics 
 
The term epigenetic refers to changes 
in gene expression without any 
alteration in the actual DNA sequence. 
It plays an important role during 
embryogenesis and during cell 
differentiation. It is the explanation why 
cells of a multi-cellular organism that all 
carry an identical genome (DNA 
sequence) can differentiate to cells with 
very diverse and specialized 
function.117,118  
Epigenetic modulation of gene 
expression is also a hallmark of 
carcinogenesis.119 The field has gained 
increasing interest during the last 
decade, especially when drugs with 
epigenetic modulating properties were 
approved for the treatment of cancer 
patients. There are three principally 
different ways of epigenetic modulation 
of gene expression; DNA methylation, 
histone modifications and RNA inter-
actions. 
 
2.3.1.1 DNA methylation 
 
DNA methylation is the most studied 
epigenetic mechanism of gene 
expression regulation and refers to the 
addition of a methyl group at position 5 
on cytosine nucleosides of the DNA. 
DNA methylation occurs predominantly 
at sites where the cytosine is followed 
by a guanine residue (CpG).120 CpG 
sites are unevenly distributed through 
the genome. Regions that are 
particularly rich in CpGs are called 
CpG-islands and are often located 
downstream to or in close proximity to 
gene promoters. In contrast to most 
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 CpGs of the genome, which normally 
are methylated, CpG-islands are 
normally unmethylated. An 
unmethylated promoter usually allows 
for gene expression and methylation of 
the promoter causes silencing of the 
gene.121 The exact mechanism by 
which promoter methylation causes 
silencing of the gene is somewhat 
unclear but could include direct 
interference with the binding of 
transcription factors, blocking of the 
transcription machinery by the 
recruitment of methyl-binding domain 
proteins to methylated DNA, or 
alteration of chromatin structure.122
 
DNA methylation is catalyzed by DNA 
methyltransferases (DNMTs), enzymes 
that transfer a methyl group from a 
methyl donor to the cytosine residue of 
the DNA. In mammals there are four 
DNMTs. DNMT1, with high affinity for 
semi-methylated DNA, maintains the 
methylation pattern during replication 
while DNMT3a and DNMT3b are mainly 
responsible for de novo methylation. 
DNMT2 does not methylate DNA to any 
significant extent but seems to be 
involved in methylation of small 
RNAs.123,124
  
2.3.1.2 Histone modification 
 
Histones are proteins forming the 
nucleosomes around which the DNA is 
wrapped to form the chromatin. Each 
nucleosome consists of two copies 
each of histone H2A, H2B, H3 and H4. 
Depending on how tight the DNA is 
packed around the nucleosomes the 
chromatin will be either condensed 
(heterochromatin) and inactive as e.g. 
during mitosis, or relaxed (euchromatin) 
and available for transcription.125 H3 
and H3 carry “tails” (the amino-terminal 
end of these proteins) that can be 
modified by e.g. acetylation and 
methylation, modifications that are 
responsible for the switch between 
heterochromatin and euchromatin and 
thereby influence gene expression. The 
acetylation status of histones is 
determined by the relative activities of 
histone acetyltransferases (HAT) and 
histone deacetylases (HDAC).126 DNA 
is negatively charged and is detached 
from the nucleosomes when acetyl 
groups are transferred by HAT from 
actyl-CoA to neutralize the positively 
charged lysine residuals of the histone 
tails. The acetylated state of histones is 
accordingly associated with eu-
chromatin and the deacetylated state 
with heterochromatin.127
 
2.3.1.3 RNA interference 
 
In 2006 Drs. Andrew Z. Fire and Craig 
C. Mello were awarded with the Nobel 
Prize in Physiology or Medicine for their 
work in the field of RNA interferance.128 
Apart from being a physiologic cellular 
mechanism to regulate gene 
expression, RNA interference is also 
used as a method to inhibit the 
expression of specific genes in vitro. 
RNA interference starts with the 
cleavage of long double stranded RNA 
by an endonuclease, Dicer. The 
product, short interfering RNAs 
(siRNAs) have an overhang of two 
unpaired nucleotides on each of the 3’ 
ends. The anti-sense strand of the 
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 siRNA then forms a complex (RISC) 
with a protein with RNase activity 
(Ago2) and guides the complex to the 
target RNA, which is cleaved. After 
cleavage, the target RNA lacks the 5’ 
cap and the 3’ poly-A tail, elements 
responsible for RNA stability, and is 
accordingly further degraded and the 
corresponding RNA can no longer be 
synthesized.129  
 
 
 
 
 
Figure 3: Chromatin structure (Felsenfeld & Groudine, Nature 2003)125 
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 2.3.2 Epigenetics in cancer with focus on MDS and AML 
 
Carcinogenesis involves gradual 
accumulation of genetic as well as 
epigenetic aberrations during disease 
progression. Typical epigenetic 
changes in both solid tumors and in 
hematological malignancies include 
genome wide (global) hypomethylation 
and promoter hypermethylation and 
hence silencing of e.g. tumor 
suppressor genes.119,130-132 The pattern 
of epigenetic alterations (promoter 
methylation best studied) is tumor-type 
specific.133,134 It is not understood why 
e.g. certain gene promoters get 
methylated in one type of cancer but 
not in another and in most cases a 
causative role of the epigenetic 
alteration in the development of cancer 
has not been demonstrated. Cancer is 
also associated with imbalance in the 
histone modification pattern by e.g. 
increased histone acetylation due to 
impaired activity of HATs, or over 
expression of HDACs as well as 
recruitment of HADCs by fusion 
proteins produced from chromosomal 
translocations, as e.g. PML-RARα in 
APL.135,136
 
Aberrant promoter hypermethylation 
has been described in both MDS and in 
AML. Commonly hypermethylated 
genes in both MDS and AML include 
P15ink4b (P15), E-cadherin (CDH), 
Hypermethylated in Cancer 1 (HIC), 
and Estrogen receptor (ER).137,138 
However also clear differences in the 
methylation pattern between de novo 
AML and MDS or MDS-AML have been 
shown using microarray assays to 
analyze methylation in bone marrow 
progenitors. Patients with MDS and 
MDS-AML show a more extensively 
aberrant methylation pattern than de 
novo AML. Moreover, the epigenetic 
changes tend to affect different 
chromosomal regions in de novo AML 
and MDS/MDS-AML.139 
 
In MDS, promoter hypermethylation 
increases with progression towards 
AML.140,141 Hypermethylation of e.g. 
P15, CDH, HIC and ER in different 
combinations, has in MDS been shown 
to correlate with an increased rate of 
leukemic transformation and poor 
survival.137,142,143 In one of the papers 
included in this thesis we show a strong 
negative correlation between CDH 
methylation and the ability for patients 
with high-risk MDS and MDS-AML to 
achieve CR on induction chemo-
therapy.144 In AML, one study show 
improved survival among patients  with 
methylated ER promoter.145   Regarding 
the impact of P15 and CDH methylation 
in AML results are somewhat 
contradictory as studies have shown 
association with both poor and good 
prognosis.146-150 The inconsistency in 
results regarding the role of methylation 
in AML treatment may reflect different 
proportions of MDS-AML vs. de novo 
cases in these studies. In the third 
study of this thesis, encompassing a 
cohort of de novo AML only, we show 
better survival in P15 methylated 
patients and higher CR-rates in patients 
with low global methylation levels.151  
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 2.3.3 Epigenetic therapies 
 
2.3.3.1 Hypomethylating drugs 
 
Azacitidine (5-azacitidine; Vidaza®) and 
decitabine (5-aza-2’-deoxycitidine; Da-
cogen®) are two structurally related 
drugs with DNA hypomethylating 
properties. Azacytidine was approved 
by the FDA in 2004 for the treatment of 
patients with myelodysplastic 
syndromes, and Decitabine for the 
same indication in 2006. Since 2009, 
azacitidine is approved also in Europe 
and in most other parts of the world. 
The drugs are related to cytarabine, a 
cytotoxic drug that has been used e.g. 
in the treatment of AML for many years. 
First synthesized in 1964, azacitidine 
was also used, in higher doses in the 
treatment of AML but was soon 
abandoned due to considerable toxicity, 
mainly gastrointestinal.152 Both 
azacitidine and decitabine act as 
cytosine analogs. After phosphorylation, 
azacitidine can be incorporated into 
DNA as well as RNA whereas 
decitabine will be incorporated solely 
into DNA. They exert their 
hypomethylating effect by inhibition of 
DNMTs, thereby blocking the addition 
of methyl groups to the new DNA strand 
during mitosis.153 Their exact 
mechanism of action in vivo is not 
known but in vitro studies on myeloid 
cells (mainly cell line experiments) have 
shown a broad spectrum of effects 
including DNA hypomethylation, re-
expression of aberrantly silenced 
genes, induction of apoptosis, 
immunomodulation, differentiation of 
blasts, histone modifications and 
inhibition of RNA methylation.154-163 The 
fact that several courses usually are 
required to achieve a response 
suggests that the clinical effect is not 
merely cytotoxic but probably also 
associated with epigenetic alterations in 
the cancer cells.164  
 
The approval in the US followed a 
randomized study on azacitidine vs. 
best supportive care for MDS patients, 
showing prolonged time to the 
composite endpoint of leukemic 
transformation or death in the 
azacitidine arm. Positive effect was 
seen also in patients with high-risk 
MDS, a group where so far no other 
therapy than allogeneic stem cell 
transplantation had proved to alter the 
natural course of the disease and 
actually improve survival.164 The effect 
on survival was later confirmed in a 
subsequent large randomized trial on 
high-risk MDS and MDS-AML, where 
azacitidine was compared to 
physician’s choice of conventional care 
regimen (CCR) (supportive care only, 
low-dose cytarabine or intensive 
induction chemotherapy). The two-year 
survival was 50.8% in the azacitidine 
treated group compared to 26.2% in the 
CCR group with an overall prolongation 
of survival of 9 months. Azacitidine was 
beneficial also in the group with poor 
risk cytogenetic, and patients with 
monosomy 7 or del(7q) responded 
particularly well.165. Later publications 
using the same material have shown a 
significant survival advantage also in 
subgroups; patients above or younger 
than 75 years, and WHO MDS vs. 
WHO AML.166,167 The effect of 
azacidine has been studied in different 
clinical situations in a large number of 
phase I and II trials. A positive effect 
was observed in patient with low-risk 
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 MDS and cytopenia.168,169 Effects in 
high-risk MDS were also seen in clinical 
trials using decitabine, including two 
randomized phase III trials. However, 
these studies did not show statistically 
significant improvement in OS.170,171 
Overall response rates with 
hypomethylating agents are usually 
around 50% but CR-rates are much 
lower, 10-20%.164,165,170,171 However, 
CR does not seem to be required for 
improved survival.172  Methylation of the 
P15 promoter decreases during 
treatment but the results are 
contradictory regarding the association 
between promoter pre-treatment 
methylation status and response to 
hypomethylating agents.173,174 
 
Hypomethylating agents has also been 
studied as part of the conditioning 
regimen for patients with relapse after 
allogeneic stem cell transplantation, 
and as maintenance after allogeneic 
SCT.175-179 Several phase II studies 
have evaluated the effect of azacitidine 
in combination with other drugs 
including lenalidomide, thalidomide and 
HDAC inhibitors.180-184 In these studies 
it is difficult to separate the effect of 
azacitidine from other drugs and 
immune effects such as the graft vs. 
host effect. One of the papers included 
in this thesis is a phase II study on 
azacitidine given as maintenance 
therapy as an attempt to prolong the 
otherwise short CR duration for patients 
with high-risk MDS and MDS-AML in 
CR after induction chemotherapy.185  
 
There are no large studies on the 
efficacy of hypomethylating agents in 
pure de novo AML material. However 
subgroup analyzes from MDS studies 
including MDS-AML or studies on AML 
cohorts including both MDS-AML and 
de novo cases show a positive effect 
also in patients with AML.166,186  
 
 
 
 
 
Figure 4: Structure of cytosine analogs (O’Dwyer & Maslak, Exp Opin Pharmacother 
2008)152 
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 2.3.3.2 Histone deacetylation inhibitors 
 
Inhibitors of histone deacetylase are 
quite new in cancer treatment. 
However, members of the first 
generation of HDAC inhibitors (short 
fatty acids, e.g. valproic acid and butyric 
acid) have been used to induced 
transcription of HbF in patients with 
sickle cell anemia for several years.187 
Suberoylanilide hydroxamic acid 
(SAHA; vorinostat; Zolinza®), a 
member of another group of HDAC 
inhibitors, was recently approved for the 
treatment of cutaneous T-cell 
lymphomas.188 HDAC inhibitors bind to 
a Zn2+ ion, critical for the enzymatic 
activity of HDACs, and different HDAC 
inhibitors have varying potency and 
specificity to specific HDAC 
isoenzymes.189,190 HDAC inhibitor 
treatment in vitro leads to rapid 
increase in acetylated histones and 
changed chromatin structure. The 
mechanisms of action of HDAC 
inhibitors are not fully understood. It has 
been suggested that the effect in 
cancer might be due to restoral of 
aberrant changes in chromatin structure 
and thus re-expression of aberrantly 
silenced genes involved in e.g. 
apoptosis and cell cycle control. Most 
certainly however, the effect of HDAC 
inhibitors is not solely related to 
chromatin structure but involve also 
other non-histone related mechan-
isms.191  
 
The effect of HDAC inhibitors have 
been evaluated in several clinical phase 
I and II trials, both as single therapy and 
in combination with hypomethylating 
agents. A problem has been dose-
limiting gastrointestinal and sedative 
side effects.  
 
Phase I and II studies have evaluated 
valproic acid, originally an anti-epileptic 
drug, as single therapy or in 
combination with ATRA in mixed MDS 
and AML. Most studies show response 
rates of 20-30%, the majority being only 
hematologic improvement and with few 
PR and CR.192-196 The addition of ATRA 
does not seem to increase the 
response 192,193 and combinations with 
hypomethylating agents show response 
rates similar to hypomethylating agents 
alone.182,184,197  
 
Vorinostat (SAHA) has also been 
evaluated in clinical phase I trials in 
MDS and AML. In a study on vorinostat 
in single therapy 7/31 (22%) patients 
with AML responded with 2 CR and 2 
CRi.198 Preliminary reported phase I 
studies of the combination vorinostat 
and hypomethylating drugs for patients 
with MDS and AML, have shown 
promising results with an overall 
response rate of 83%  (53% CR or CRi) 
for the combination vorinostat and 
azacitidine.199,200 
2.4 Apoptosis 
 
Apoptosis is a form of programmed cell 
death. It is an energy dependent 
controlled process and it does not 
cause inflammation which is different 
from cell death in necrosis.201 Apoptosis 
is essential in embryonic development 
and in protection of the organism by 
removal of cells that are damaged from 
e.g. viruses, mutations, toxic drugs or 
radiation.202 Morphologically apoptosis 
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 is characterized by cell shrinkage, 
condensation of nucleus and chromatin, 
break down of DNA, nuclear 
fragmentation, formation of apoptotic 
bodies and finally phagocytosis by 
macrophages.203 Apoptosis can be 
triggered either via the extrinsic or the 
intrinsic pathway. These pathways, 
however, are not totally independent 
from each other. The extrinsic pathway 
includes interaction between so-called 
death receptors and their ligands and 
subsequent activation of caspases. The 
stimulus can be e.g. binding of Fas 
ligand to Fas receptor, withdrawal of 
growth factor stimulus, or T-cell 
mediated. The intrinsic pathway 
includes activation of mitochondria and 
release of cytochrome c, as a response 
to e.g. DNA damage. The apoptosis 
pathways are controlled by a wide 
number of pro- (e.g. Bid and Bax) and 
anti-apoptotic proteins (e.g. Bcl-2 and 
BclXL).204 In tumorogenesis, 
dysregulation of apoptosis and 
disturbances of cell cycle regulation is 
considered necessary for tumor 
progression.205 Mutation of the P53 
gene, coding for a key pro-apoptotic 
protein and important for the induction 
of apoptosis in response to DNA 
damage, is common in cancer and 
often associated with poor prognosis 
and poor response to chemotherapy.206 
Over expression of the anti-apoptotic 
protein Bcl-2 is also well known in 
several tumor types.207 Apoptosis in the 
pathogenesis of MDS is discussed in 
section 2.1.4. 
 
 
 
 
Figure 5: Apoptotic pathways. Extrinsic pathway – Death receptor in cell membrane. 
Intrinsic pathway - Mitochondria (Hengartner, Nature 2000)204 
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 3 AIM OF THE THESIS 
 
 
The aim of this thesis was to elucidate the role of DNA methylation in high-risk MDS 
and also in AML, thereby improving the possibility to better patients for the optimal 
therapy, and evaluate mechanisms and utility of the hypomethylating drug azacitidine. 
Specific aims were: 
 
I. To investigate the correlation between promoter methylation and the 
outcome of induction therapy in patients with high-risk MDS and MDS-AML. 
 
II. To evaluate the use of azacitidine as maintenance therapy for patients in CR 
after induction chemotherapy with the hypothesis that it could prolong the 
otherwise short CR duration. 
 
III. To study the prognostic impact of promoter methylation as well as global 
DNA methylation in a de novo AML population and compare these results to 
the pattern observed in high-risk MDS and MDS-AML. 
 
IV. To assess the mechanisms of action of azacitidine in primary MDS and 
normal bone marrow progenitors.  
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 4 MATERIAL AND METHODS 
 
4.1 Patients 
 
4.1.1 Paper I and II 
 
Sixty consecutive patients with inter-
mediate-2 and high-risk MDS, CMML 
with >10% blasts, and AML following an 
established MDS phase were eligible 
for the protocol. Patients should be 
deemed fit for at least one course of 
standard induction chemotherapy and 
were excluded if they were considered 
candidates for potentially curative 
regimens, including AML-like induction 
chemotherapy followed by intensive 
consolidation chemotherapy or 
allogeneic stem cell transplantation. 
Hence, the study was designed mainly 
for older patients or patients with 
multiple risk factors. Initial diagnosis as 
well as verification of CR was assessed 
at the central hematopathology unit at 
Karolinska University Hospital. For 
diagnosis, the WHO 2001 criteria were 
applied. Cytogenetic analyzes were 
done locally at each center by standard 
techniques and the findings were 
classified according to the IPSS into 
good, intermediate or poor prognostic 
karyotypes. 
 
4.1.2 Paper III 
 
The study population consisted of two 
cohorts. 1. De novo AML; a total of 107 
previously untreated AML patients 
diagnosed at the Karolinska University 
Hospital at Huddinge were included in 
the study. Patients with APL or a 
previous history of MDS were excluded. 
2. A cohort of 60 patients with 
Intermediate-2 or high-risk MDS, or 
AML following MDS, who were included 
in the above-described clinical study. 
For diagnosis and classification of CR 
and progression in the AML cohort, 
WHO criteria were applied. 
Chromosome banding and mutation 
analyzes of FLT3, NMP1, CEBA and 
NRAS were performed using standard 
techniques. 
 
4.1.3 Paper IV 
 
For this in vitro study, we used bone 
marrow samples from patients with 
high-risk MDS or CMML-2 and from 
healthy controls. Patients were 
previously untreated with chemotherapy 
and hypomethylating agents and were 
sampled at the time of diagnosis or at 
progression from low-risk to high-risk 
MDS. All patients and normal controls 
gave their informed consent before 
sampling.
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 4.2 Study design and treatment 
 
4.2.1 Paper I and II 
 
Induction chemotherapy consisted of a 
standard DA 2+7 regimen: daunorubicin 
60 mg/m2 days 1 and 2 and cytarabine 
150 mg/m2 days 1 to 7. Patients that did 
not respond to the first course were 
given a second induction course if 
judged medically appropriate. Criteria 
for CR were <5% bone marrow blasts, 
stable hemoglobin >100 g/l, WBC 
>1.5x109/l with normal differential count, 
and platelets >100x109/l. 
 
Patients achieving CR were treated with 
azacitidine 60 mg/m2 s.c. 5/28 days 
until disease progression or 
unacceptable toxicity. The initial dose 
was 75 mg/m2 but the protocol was 
amended due to several observations 
of grade IV neutropenia in the first 5 
enrolled patients. Further reduction of 
the azacitidine dose was also allowed 
to avoid hospitalization and severe 
cytopenias. 
 
Bone marrow for methylation analysis 
was sampled before induction 
chemotherapy, at CR and then 6, 12 
and 24 months after CR. 
 
4.2.2 Paper III 
 
This was a retrospective study on two 
cohorts of patients. Treatment of the 
MDS cohort is described in 4.2.1. For 
the de novo AML cohort, induction 
chemotherapy including cytarabine and 
an anthracycline, was given according 
to national guidelines for acute myeloid 
leukemia. Patients who achieved CR 
were given standard consolidation 
courses according to national 
guidelines or study protocol, or 
underwent allogeneic stem cell 
transplantation. The bone marrow 
samples used in this study were 
obtained at diagnosis, prior to the first 
induction course. 
 
4.3 Cell sampling and cell sorting (Paper I-IV) 
 
Bone marrow was obtained from 
patients and normal controls. Mono-
nuclear cells (MNC) were separated by 
density gradient technique through 
Lymphoprep. When the yield of MNCs 
was sufficient, CD34+ cells were 
purified by magnetic cell sorting using 
the CD34 Progenitor Isolation Kit 
according to the manufacturer’s 
guidelines. For paper IV MNCs or 
CD34+ cells were used directly for 
suspension cultures whereas for paper 
I-III cells were stored as pellet in -80°C. 
For the Nordic multicenter study (paper 
I and II), bone marrow was shipped to a 
central laboratory (DHL <24 hours 
service) in order to avoid the effect of 
local separation techniques and storage 
factors. Cell line experiments were 
done on the P39 myeloid cell line that 
was originally derived from a patient 
with CMML. 
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 4.4Suspension cultures (Paper IV) 
 
Cells were plated at a concentration of 
1x106 cells/ml (P39 experiments 
0.25x106/ml) in RPMI 1640-Glutamax 
with the addition of 10% fetal bovine 
serum. G-CSF (10 ng/ml), IL-3 (10 
ng/ml) and stem cell factor (25 ng/ml) 
was added to cultures of primary cells. 
Cells were cultured for 24 hours at 37°C 
and in 5% CO2, prior to adding 
azacitidine. Azacitidine was diluted in 
sterile H2O, filtered through 0.22 µm 
plastic syringe filter, and added to the 
cultures in final concentrations from 
0.05 to 10 µM. Cells were incubated for 
24, 48 and in some cases 72 hours and 
cell count and viability was checked 
with Trypan blue. Cells were harvested 
and analyzed for viability, cell count, 
apoptosis and DNA methylation. Gene 
expression profiling was done on cells 
cultured for 24 hours with and without 
azacitidine 0.5 µM. 
    
4.5 Colony assays (Paper IV) 
 
To explore the effect of azacitidine on 
colony growth, we exposed CD34+ 
normal and MDS progenitor cells to 
azacitidine (0.05-10µM) for 24 hours. 
Cells were then washed once in PBS, 
re-suspended in fresh medium, mixed 
with 4 ml of MethoCult medium 
GFH4434 and plated in triplicates (1 
ml/dish) on small Petri dishes. Dishes 
were incubated at 37°C and 5% CO2 for 
14 days. Erythroid colonies (CFU-E and 
BFU-E) and myeloid colonies (granu-
locytic colonies, CFU-G, monocytoid 
colonies, CFU-M and mixed granu-
locytoid/monocytoid colonies, CFU-GM) 
were counted and a mean value was 
calculated for each position. 
 
4.6 DNA extraction (Paper I-IV) 
 
Genomic DNA was extracted from MNC 
and CD34+ cells using QiAmp DNA 
mini kit (paper I and II) or Gene Elute 
Genomic DNA extraction kit (paper III 
and IV) according to manufacturer’s 
guidelines. The amount of DNA was 
measured by spectrophotometry and 
DNA was stored at -20°C.  
  
4.7 RNA extraction (Paper IV) 
 
RNA for gene expression profiling was 
extracted from around 0.5 x 106 cells 
using the RNeasy plus mini kit 
according to the manufacturer’s 
guidelines. The final elution step was 
repeated twice with 30 and 20 µl 
respectively of the elution buffer. The 
RNA was stored in the elution buffer at -
80°C. 
 
4.8 Bisulfite modification (Paper I-IV) 
 
During bisulfite modification of DNA 
cytosine residues are deaminated to 
uracil but methylated cytosine remains 
unchanged. This will give methylated 
and unmethylated DNA different 
properties, which can be assessed by 
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 different methylation assays (see 
below). For paper I-III this was done 
manually as previously described.208 In 
brief 2.5 µg of DNA were denaturated in 
NaOH for 15 minutes at 37°C followed 
by the incubation in sodium bisulfite at 
55°C for 16 hours. Thereafter, DNA was 
recovered using the GeneClean II kit, 
desulfonated in NaOH and precipitated 
in ethanol. For paper IV bisulfite 
modification of DNA was done using the 
EZ methylation gold kit according to the 
manufacturer’s instructions. 
 
4.9 Polymerase chain reaction (PCR) (Paper I-III) 
 
PCR specific for bisulfite-reacted P15, 
CDH and HIC promoters was carried 
out in a final volume of 25 µl containing 
50 to 100 ng of bisulfite modified DNA, 
1x TEMPase PCR buffer I with 1.5 mM 
MgCl2, 0.2 mM cresol red and 12% 
sucrose, 0.2 mM dNTP, 0.5 µM each 
forward and reverse primers,137 and 
0.75 units of TEMPase HotStart DNA 
polymerase. The polymerase was 
activated by incubation at 95°C for 15 
min followed by 40 cycles of 95°C for 
30 s, 55°C (P15 and HIC) or 48°C 
(CDH) for 30 s, 72°C for 30 s and a final 
extension at 72°C for 5 min. PCR was 
performed in a PX2 Thermal cycler and 
PCR products were examined by 
electrophoresis in a 2.5% agarose gel.
4.10 Promoter methylation by DGGE (Paper I-III) 
 
In the denaturing gradient gel 
electrophoresis (DGGE) methylated 
and unmethylated DNA can be 
separated on a denaturing gel due to 
their different denaturing properties 
from the bisulfite treatment described 
above.209 15-20 µl of the PCR product 
(see 4.8) were loaded to a 10% 
denaturant/ 6% polyacrylamide - 70% 
denaturant/ 12% polyacrylamide double 
gradient gel. A fully methylated control 
and an unmethylated control were also 
loaded to each gel. Gels were run for 
270 minutes in 1x Tris acetate/ EDTA 
buffer kept at a constant temperature of 
58°C for P15 or 55°C for CDH and HIC. 
Gels were then stained in 1x Tris 
acetate/ EDTA buffer containing 
ethidium bromide (2 µg/ml) and 
photographed under UV illumination. 
Methylated DNA denaturate later during 
the electrophoresis. Samples where 
bands were seen under the level of the 
unmethylated control were classified as 
methylated. 
 
4.11 Promoter methylation analysis by melting curve analysis (Paper III) 
 
Methylation specific melting curve 
analysis was performed for P15, CDH 
and HIC using the same PCR product 
as for DGGE. After bisulfite modification 
of DNA (see 4.7), methylated and 
unmethylated DNA will have different 
melting temperatures depending on 
their difference in CG content. We 
performed the melting curve analysis as 
previously described by Guldberg et 
al.210 
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Figure 6: Example of DGGE results. 
PBL: Unmethylated control/ DNA from 
peripheral blood lymphocytes from 
healthy controls. SssI: Positive control/ 
in vitro methylated. 1, 2 and 3: Patient 
samples. Patient 1 methylated. Patient 
2 unmethylated. Patient 3 methylated. 
 
 
4.12 Promoter methylation analysis by pyrosequencing (Paper III and IV) 
 
Pyrosequencing technology was 
applied to analyze the methylation 
levels at specific CpG-sites in p15ink4b 
and CDH promoters (Paper III and IV) 
and LINE-1 repetitive elements (Paper 
IV). Primer sequences for P15 and 
CDH are available in pyrosequencing 
assay data base (http://techsup-
port.pyrosequencing.com). LINE-1 el-
ements methylation was analyzed as 
previously described.211 HotStar Taq 
polymerase and HotStar Taq master 
mix kit were used to amplify 1.5 µl of 
bisulfite treated DNA.  Cycling 
conditions were: 95°C for 15 min, 40 x 
(95°C for 20 s, 53°C for 20 s and 72°C 
for 20 s), 72°C for 10 min and then 4°C. 
Epi Tect PCR control set  was used as 
100% methylated, 50% methylated and 
unmethylated controls for the reactions. 
More than 10% change in the mean 
degree of methylation of the examined 
CpG-sites, treated samples vs. un-
treated control, was considered 
physiologically significant. 
 
4.13 Global methylation by LUMA (Paper III and IV) 
 
Luminometic Methylation Assay 
(LUMA) was used to measure global 
DNA methylation.212 In brief, 500 ng of 
genomic DNA was incubated in parallel 
reactions with a pair of enzymes with 
endonuclease activity (recognition 
sequence CCGG). One (HpaII) is 
unable to cut DNA if the cytosine is 
methylated (CmetCGG) whereas the 
other (MspI) cuts both methylated and 
unmethylated DNA. Both MspI and 
HpaII leave 5’ CG-overhangs after 
cleavage, which are filled in a 
polymerase extension assay during 
stepwise addition of dCTP and dGTP 
where inorganic pyrophosphate is 
released and converted to ATP. ATP is 
then used by luciferase to convert 
luciferin to oxyluciferin, a step where a 
small amount of visible light, 
proportional to the ATP produced, can 
be detected and measured. A ratio 
between the results from the HpaII and 
MspI reaction is then calculated. If DNA 
is completely unmethylated the 
HpaII/MspI ratio would be 1.0 and for 
100% methylated DNA the ratio would 
approach 0.  The assay was carried out 
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 in duplicates.  More than 5% change in 
the HpaII/MspI ratio, treated samples 
compared to un-treated controls, was 
considered a physiologically significant 
alteration.
 
4.14 Whole genome “promoter” methylation by Illumina (Paper III) 
 
Bisulfite modified DNA from a total of 20 
samples was evaluated for genome 
wide promoter methylation using the 
Illumina Infinitum HumanMethylation27 
bead array. This analysis was made at 
the core facility of the Karolinska 
Institute as previously described.213 
This detects the methylation level of 
27.578 individual CpG sites spread 
across the promoter regions of 14.495 
genes. 
 
4.15 FISH (Paper IV) 
 
Fluorescence in situ hybridization 
(FISH) is widely used to detect genetic 
aberrations with specific DNA probes 
both for whole chromosomes and short 
sequences. Cells from azacitidine 
treated and untreated cultures (see 4.3) 
were collected and spread onto slides 
by cyto-centrifugation. Probes were 
selected according to the patient’s 
known specific aberrations at diagnosis, 
centromer probe CEP8 and 7q31/7 
centromer probe. The manufacturer’s 
protocols were used. Signals were 
counted in 20-200 cells depending on 
yield from the cultures. 
 
4.16 Gene expression profiling (Paper IV) 
 
RNA quality and concentration were 
measured using an Agilent 2100 
bioanalyzer and Nanodrop ND-1000, 
respectively. cDNA was generated with 
the GeneChip Whole Transcript (WT) 
cDNA Synthesis and Amplification kit 
(Affymetrix) using 300 ng total RNA and 
labeled using the GeneChip WT 
Terminal Labeling Kit (Affymetrix) 
according to the manufacturer’s 
specifications. Labeled cRNA was 
hybridized to oligonucleotide probes on 
a GeneChip Human Gene 1.0 ST array 
(Affymetrix) containing 764,885 probes 
representing 28,869 genes, and 
washed according to manufacturer’s 
guidelines. Image analysis was 
performed using Affymetrix Command 
Console and the arrays were scanned 
using a GeneChip Scanner 3000 
(Affymetrix). Pre-processing was 
performed using Affymetrix Expression 
Console (Summarization: PLIER, 
Background correction: PM-GCBG, 
Normalization: Global Median). The 
number of highly significant differences 
between untreated and azacitidine 
treated MDS were too low to allow for 
any proper pathway analysis to be 
done. 
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 4.17 Flow cytometry for apoptosis (Paper IV) 
 
Cells (0.5x106/ position) from 
suspension cultures (see 4.3) were 
harvested at 24 and 48 hours for 
analysis of the apoptotic cell fraction by 
FACS. The cells were washed once in 
PBS and re-suspended in the 
flourochrome solution (0.1% sodium 
citrate (wt/v), 0.1% Triton X-100 (v/v) 
and propidium iodide 50 mg/l in distilled 
H2O). Cells were then incubated at 4°C 
for 1 hour and then analyzed on a 
FACS Calibur cytometer using 
CellQuest Pro software. Propidium 
iodide stains DNA and accordingly cells 
with low amount of DNA (apoptotic 
cells) will be weekly stained.214
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 5 RESULTS AND DISCUSSION 
 
5.1 Paper I: Negative effect of DNA hypermethylation on the outcome of 
intensive chemotherapy for patients with high-risk myelodysplastic syndromes 
or acute myeloid leukemia following myelodysplastic syndromes 
 
Sixty patients were enrolled in the 
study. Baseline characteristics of the 
patients are shown in Table 6. CR was 
achieved in 24 patients (40%), which is 
in line with previous studies of induction 
chemotherapy in similar groups of 
patients.99-102 The CR rate was higher in 
patients with MDS (59%) and CMML 
(50%) than in patients with MDS-AML 
(30%). However, these differences in 
CR rates were not statistically 
significant (P=0.07). Previous studies 
have shown that pre-treatment 
variables indicative of a more 
proliferative disease are associated with 
a lower CR rate.99-102 In this study, a 
high WBC correlated negatively to CR 
(P=0.03).
 
 
Table 6: Baseline characteristics of 60 enrolled patients 
 
 N=60 
N (%) 
Median (Range) 
Sex 
       Male 
       Female 
 
40 (67) 
20 (33) 
 
Age  68 (54-83) 
Diagnosis (WHO) 
       MDS 
       MDS-AML 
       CMML 
 
17 (28) 
37 (62) 
  6 (10) 
 
Cytogenetic risk group (IPSS) 
       Good 
       Intermediate 
       Poor 
       Not done/unsuccessful  
 
25 (42) 
10 (17) 
17 (28) 
  8 (13) 
 
Hemoglobin (g/L)  95 (62-122) 
WBC (109/L)  4.3 (0.8-90.9) 
Platelets (109/L)  65 (5-381) 
S-LDH (µkat/L)  4.8 (1.9-27) 
Bone marrow cellularity (%)  90 (30-100) 
Blasts in bone marrow (%)  23 (6-98) 
CD34+ in bone marrow (5%)  10 (1-82) 
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 The main focus of this paper was to 
evaluate the impact of promoter 
methylation on outcome of induction 
chemotherapy. Moreover, we wanted to 
assess the relation between promoter 
methylation and a set of previously 
known risk factors in MDS. Bone 
marrow samples for methylation 
analyzes of P15, CDH and HIC were 
obtained from 50 patients. In 23/50 the 
yield of MNCs was too low to allow for 
further CD34+ sorting. However, there 
was a high concordance between 
methylation results from MNCs and 
CD34+ cells (P<0.001). Only one 
patient showed P15 in MNCs but not in 
CD34+ cells. Overall, 55% of the 
patients showed hypermethylated P15, 
whereas 37% and 22% were 
hypermethylated at the CDH or HIC 
promoters, respectively. These 
frequencies are comparable to previous 
methylation results in MDS materials.137
 
Promoter hypermethylation in MDS is 
reported to increase with disease 
progression and to be more frequent in 
higher age groups.142,151 In our cohort, 
promoter hypermethylation was more 
frequent in MDS-AML compared to 
MDS or CMML (P=0.02). Methylation 
also increased with increasing bone 
marrow blasts and CD34+ cells in the 
bone marrow. (P=0.007 and 0.04). 
Methylation of all three genes was more 
common in older patients (P=0.02). 
Interestingly, there was no difference in 
methylation status between cytogenetic 
risk groups (Table 8). 
 
 
Table 8: Methylation status in relation to other pre-treatment variables 
 
 P15 methylated P15 + one methylated gene All three genes methylated 
 Yes No P Yes No P Yes No P 
Sex (m/f) 19/7 12/9 0.36 11/4 16/12 0.34 5/1 24/15 0.40 
Age1 70.3±6.3 67.4±5.6 0.12 71±6 68.2±5.6 0.07 74.2±6.5 68.4±5.4 0.02 
Diagnosis2 18/8 10/11 0.15 13/2 13/15 0.02 5/1 21/18 0.22 
Cytogenetics3 10/12 5/16 0.20 6/5 7/21 0.13 1/4 13/23 0.65 
Hb1 97.3±9.6 93.5±16.0 0.33 96.1±10.7 95.9±14.6 0.97 96.8±9.4 95.1±13.3 0.76 
WBC1 12.0±13.7 11.3±18.2 0.89 13.1±14.5 9.9±16.1 0.52 12.4±10.9 11.8±16.8 0.93 
Platelets1 95.3±84.6 104.9±105.5 0.73 75.1±70.8 106.8±97.6 0.29 75.8±50.1 98.4±93.0 0.57 
LDH1 5.7±4.0 6.8±0.5 0.50 4.8±2.2 6.5±5.0 0.31 5.1±2.7 6.5±5.0 0.59 
Cellularity 
(%)1,4
81.0±21.3 80.0±24.0 0.90 75.6±6.0 80.0±21.6 0.56 80.8±30.7 80.0±21.7 1.00 
Blasts (%)1,5 37.2±28.7 27.7±22.5 0.24 49.0±31.1 25.0±20.3 0.007 49.0±32.2 30.8±25.7 0.16 
CD34+ (%)1,6 28.0±29.6 10.3±7.8 0.04 33.8±31.7 11.9±11.2 0.01 36.8±33.3 19.1±23.3 0.16 
1Mean ± SD 2Diagnosis AML vs. not AML 3Cytogenetic group poor vs. not poor 4Bone marrow cellularity 
5Blasts in bone marrow 6CD34+ phenotyping of bone marrow cells 
 
A key finding of in this paper was that 
promoter hypermethylation of CDH 
(P=0.008) or P15 plus at least one 
other gene (P=0.05) was associated 
with poor outcome of induction 
chemotherapy. In fact, no patient with 
all three genes methylated achieved CR 
(P=0.03). P15 methylation status alone 
showed no impact on outcome (Figure 
7). Previous studies have reported that 
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 promoter hypermethylation of e.g. P15 
is associated with poor prognosis.137,141-
143 This study is the first to show a 
correlation between methylation status 
and the outcome of induction 
chemotherapy in patients with high-risk 
MDS.  
 
When this study was designed in 2002, 
primary therapy for high-risk and 
transformed MDS in the Nordic 
countries was induction chemotherapy 
or supportive care only. Today, in the 
light of results showing a survival 
advantage for patients treated with 
azacitidine compared to conventional 
care regimens,165 the place for 
induction chemotherapy in high-risk 
MDS is unclear. Future studies are 
warranted to evaluate a possible benefit 
of intensive chemotherapy in subgroups 
of patients with high-risk MDS, e.g. 
those with rapidly proliferating disease, 
in which there may not be enough time 
to await the effect of hypomethylating 
drugs. Our results suggest that patients 
with hypermethylated CDH should not 
be offered intensive chemotherapy. If 
these results are reproduced in future 
studies, examination of promoter 
methylation status could be one way to 
select patients for optimal therapy. 
Whether pre-treatment of patients with 
hypomethylating agents could lead to a 
better response to conventional 
chemotherapy would also be worth 
analyzing in a prospective study.
 
 
 
 
Figure 7: Percentage of CR in patients with and without methylation of P15, CDH, 
HIC, P15 plus at least one other gene, or of all three genes 
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 5.2 Paper II: Maintenance treatment with azacytidine for patients with high-risk 
myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS in 
complete remission after induction chemotherapy 
 
Based on the positive results of 
azacitidine in high-risk MDS from the 
study by Silverman et al,164 we 
hypothesized that maintenance 
treatment with azacitidine given to 
patients with CR after induction 
chemotherapy could prolong the usually 
short CR duration. 98-100,102,103 Twenty-
four of 60 enrolled patients achieved 
CR. One patient underwent allogeneic 
stem cell transplantation and was taken 
off the study. The remaining 23 patients 
(median age 70 years) started 
maintenance therapy (see 4.2.1). Last 
follow up was at August 1st, 2008, 24 
months after the last patient achieving 
CR. Median follow up time was 20.0 
months (4.5-50.3). 
 
This paper was the first to report on 
feasibility and effects of maintenance 
therapy with hypomethylating agents 
after intensive chemotherapy. 
Azacitidine maintenance was well 
tolerated and only one patient stopped 
azacitidine due to an adverse event. 
The most frequent adverse events were 
grade 3 or 4 neutropenia or thrombo-
cytopenia, reported at any time point in 
43.5% and 30.5% of the patients, 
respectively. However, dose reduction 
was allowed and only 22% (grade 3) 
and 8% (grade 4) of the courses were 
associated with neutropenia of this 
magnitude. Thrombocytopenia grade 3 
was reported after only 9.5% of the 
courses and grade 4 thrombocytopenia 
was not observed. Interestingly, 
hemoglobin levels rose during the first 
courses of azacitidine in 16/23 patients. 
In the whole cohort hemoglobin was 
significantly higher before cycle 4 than 
before cycle 1 (P=0.02). Potential 
explanations include both slow natural 
recovery after chemotherapy and a 
direct positive effect of azacitidine on 
erythropoiesis.  
 
Median CR duration (13.5 months) and 
median OS (20.0 months) for the 23 
patients treated with azacitidine 
maintenance is not clearly different from 
previous studies on induction 
chemotherapy in high-risk MDS or 
MDS-AML. 98-100,102,103 However, many 
of these studies included younger 
patients and two studies on older 
patients including both de novo AML 
and MDS-AML, showed OS of only 9 
and 10 months respectively.215,216 
Although, the study was not powered 
for subgroup analysis, no difference in 
CR duration was seen between 
diagnostic or cytogenetic subgroups, or 
in patients with different P15 
methylation status. A low platelet count 
before induction chemotherapy was 
associated with shorter CR duration 
(Figure 8).  
 
As dose reduction of azacitidine was 
allowed to avoid severe cytopenias and 
hospitalization, one explanation to lack 
of clear benefit of azacitidine 
maintenance could be insufficient 
dosing. However, there was no 
difference in CR duration or OS 
between patients treated with doses 
above or below the median dose in the 
study. As few patients with any other 
promoter than P15 methylated ever 
reached CR, another explanation might 
be that those that could have benefited 
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 the most from the maintenance therapy 
never reached that stage of the study. 
Interestingly 4/5 patients with a 
karyotype including +8 reached CR and 
all 4 showed CR duration and a survival 
well above the median for the whole 
maintenance group. The only two 
patients who were hypermethylated at 
the CDH promoter and reached CR had 
very short CR-durations, 4 and 6 
months respectively. CDH methylation 
remained a negative prognostic marker 
for OS in the whole cohort of 60 
patients (4 months vs. 9.3 months, 
P=0.003). 
 
This study shows that azacitidine 
treatment is feasible following intensive 
chemotherapy. Whether there are 
subgroups of patients that can benefit 
from azacitidine maintenance remains 
to be further studied. 
 
 
Figure 8: CR duration in subgroups A) All 23 maintenance patients B) AML vs. RAEB 
and CMML C) Cytogenetics IPSS Good vs. Intermediate or Poor D) Pre-induction 
platelets above or below the median E) P15 methylated vs. unmethylated F) Mean 
dose for the patient above vs. below median for the whole group 
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5.3 Paper III: Gene-specific and global methylation patterns predict outcome in 
patients with acute myeloid leukemia 
 
Many previous studies on AML include 
both de novo AML and AML following 
MDS. It is know that e.g. certain 
cytogenetic aberrations have different 
prognostic implications in de novo AML 
and MDS-AML. Moreover, response to 
therapy differs between the two 
diseases. Based on our finding in paper 
I, we wanted to evaluate the impact of 
DNA methylation in a cohort of AML 
excluding MDS-AML. 
 
Ninety-eight patients with de novo AML 
and 9 with AML secondary to previous 
chemotherapy (for easier legibility 
referred to as de novo AML) were 
included in this retrospective study. 
Median age was 65.4 years (23-85). 
Baseline characteristics are shown in 
Table 9. CR was achieved in 75% of 
the patients which is higher than in 
most studies of induction chemotherapy 
in high-risk MDS and MDS-AML, 
including paper I  in this thesis (median 
age 68 years, 54-83) where the CR rate 
was only 40%. Allogeneic stem cell 
transplantation was performed in 24 
patients while 41 received standard 
consolidation courses. Sixteen patients 
had reduced intensity consolidation 
courses due to treatment toxicity. 
 
Table 9: Base line characteristics of 107 non-MDS AML patients 
 
Patient characteristics  
Age (years) 65 (23-85)1
Bone marrow blasts (%) 68 (20-98)1
WBC count (x109/L) 22 (0-368)1
Female/Male 66/41 
Cytogenetic risk group (low/intermediate/high) 5/77/25 
CR rate 80 (75%) 
FABsubtype 
       M0 
       M1 
       M2 
       M4 
       M5 
       M6 
       Not defined 
 
8 (7%) 
30 (28%) 
30 (28%) 
21 (20%) 
8 (7%) 
2 (2%) 
8 (7%) 
Molecular analysis (number positive/number analyzed) 
       FLT3-ITD 
       FLT3-TKD mutation 
       NPM1 mutation 
       FLT3-ITD negative and NPM1 mutated 
       CEBPA mutation 
       NRAS mutation 
 
29/95 
10/94 
34/93 
18/93 
7/95 
4/86 
1median (range) 
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 The frequency of promoter hyper-
methylation, assessed by DGGE, was 
higher in the de novo AML cohort 
compared to the MDS material, 66% for 
P15, 66% for CDH and 51% for HIC. 
However, in the MDS and MDS-AML 
cohort a higher degree of methylation 
was seen in the more advanced 
patients. Hence a higher portion of 
methylated patients could be expected 
in the AML cohort. The results from 
DGGE were validated by melting curve 
analysis (P15, CDH and HIC) and 
pyrosequencing (P15) in a subset of 
patients with good concordance, 100% 
and 79% respectively. 
  
Unlike in the MDS cohort, no 
association between methylation status 
of P15, CDH or HIC and response to 
induction chemotherapy was observed 
in de novo AML. Moreover, patients 
who were hypermethylated in the P15 
promoter had longer disease free 
survival (DFS) as well as OS than 
unmethylated patients. In studies on 
MDS P15 methylation status is 
universally associated with poor 
prognosis,137,142,143 while studies on P15 
methylation and prognosis in AML show 
conflicting results.146-150 The results in 
previous AML studies might reflect a 
varying proportion of patients with 
MDS-AML in many as well as the use of 
different methylation assays. CDH 
methylation, which was the strongest 
negative prognostic marker in the MDS 
material did not correlate to outcome in 
the de novo AML cohort. Instead, 
promoter hypermethylation of P15 as 
well as increased genome wide 
promoter methylation (Illumina 
HumanMethy-lation27 bead chip array) 
was associated with better DFS and OS 
in the de novo AML material. 
 
Next we performed a comparison of 
global methylation assessed by LUMA 
and examination of 27.578 mainly 
promoter-associated CpG sites by 
Illumina HumanMethylation27. The 
analysis confirmed the typical inverse 
correlation between global methylation 
and promoter methylation in cancer. 
Patients with low global methylation by 
LUMA showed methylation at a 
significantly larger number of examined 
CpG sites by Illumina (P=0.003). 
 
Interestingly, CR rates were higher in 
patients with low global methylation 
assessed by LUMA (P=0.05). The 
difference retained significance also in 
the multivariate analysis, when other 
known risk factors were entered. 
However, global methylation had an 
impact on the outcome of induction 
chemotherapy only in patients <65 
years and this did not translate to a 
difference in survival. Whether AML 
patients with high global methylation 
could benefit from hypomethylating 
agents before induction chemotherapy 
remains to be investigated. 
 
Differences in methylation pattern 
between high-risk MDS/MDS-AML and 
de novo AML was previously reported 
by Figueroa et al.139 We could show 
that also the prognostic value of 
methylation patterns differs between the 
two entities. These findings suggest 
that MDS-AML and de novo AML 
should be studied separately, at least in 
clinical trials of DNA methylation and 
hypomethylating agents 
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 5.4 Paper IV: Complex effects of azacitidine in primary myelodysplastic and 
normal bone marrow cell cultures 
 
Understanding the cellular mechanisms 
of azacitidine is essential for well-
designed future studies of combination 
therapies, and for optimal clinical use of 
the drug. A variety of mechanisms have 
been suggested, mostly from cell line 
experiments or sequential sampling 
during azacitidine treatment.154-163 We 
wanted to assess the effects of 
azacitidine on primary bone marrow 
progenitors from patients with high-risk 
MDS and from normal controls in vitro. 
We exposed MNC and CD34+ 
progenitors to azacitidine in suspension 
cultures and evaluated its effects on cell 
growth, colony formation, apoptosis, 
methylation, and gene expression. 
 
First we assessed the effect of 
azacitidine on cell growth and colony 
formation. Interestingly, azacitidine in 
doses up to 5 µM did not affect cell 
growth or viability in the suspension 
cultures. Actually, the absolute number 
of cells per ml was higher in azacitidine 
treated positions than in controls in 1/10 
NBM and in 4/10 MDS. Neither was 
there any inhibitory effect on colony 
formation after exposure to azacitidine 
in doses up to 0.5 µM for 24 hours. In 
fact, the number of colonies (especially 
erythroid colonies) increased by >70% 
with the lower doses of azacitidine in 
5/9 evaluable MDS and 5/13 NBM. This 
is in line with our findings in paper II 
where the hemoglobin level during 
azacitidine treatment rose in a majority 
of the patients, whereas thrombo-
cytopenia and neutropenia was 
common. It may suggest a direct 
stimulatory effect of azacitidine on 
erythropoiesis.185 The seemingly un-
toxic effect of the drug on normal bone 
marrow progenitors is a useful finding 
since it may support the use of the drug 
for patients with low-risk MDS and as 
maintenance after allogeneic stem cell 
transplantation.177,179  
 
Azacitidine did induce apoptosis also in 
our experiments on primary bone 
marrow progenitors, but to a much 
lesser degree than in previously 
reported cell line experiments from our 
group (Figure 9).156 The difference in 
apoptosis between control and 
azacitidine treated positions was not 
significant for MDS progenitors, which 
may partly be explained by the well-
described spontaneous apoptosis in 
these cultures.217 
 
Also the hypomethylating effect was 
less pronounced in MDS cultures than 
previously reported in cell line 
experiments. Promoter methylation for 
P15 and CDH was not affected by 
incubation with azacitidine. Global 
methylation assessed by LUMA 
showed no consistent pattern in 
samples from 5 NBM and only a slight 
decrease after azacitidine treatment in 
cells from 5 MDS patients (P=0.19). 
Assessment of global methylation by 
pyrosequencing for LINE-1 repetitive 
elements showed a significant decrease 
in methylation after incubation with 1 
µM azacitidine for 48 h in samples from 
NBM as well as MDS (P=0.001 and 
0.02, respectively). No further 
hypomethylating effect was observed 
with higher dose (2 µM). 
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Figure 9: Apoptotic effects of azacitidine:  
A) P39 cell line, 48 hours. Histograms showing increasing apoptotic proportion with 
increasing dose of azacitidine  
B) Percentage of apoptotic cells in P39 cell line with and without azacitidine  
C) Percentage of apoptotic cells in normal controls with and without azacitidine  
D) Percentages of apoptotic cells in MDS with and without azacitidine. 
 
We found marked differences in the 
effect of azacitidine on gene expression 
between NBM and MDS. Only 
100/3,174 (3%) genes that were 
deregulated by azacitidine in MDS were 
up-regulated. In NBM however, the vast 
majority of deregulated genes 
(1,114/1,396; 81%) were down-
regulated. In this material the number of 
significant differences in gene 
expression between untreated and 
azacitidine treated MDS samples was 
too low to allow for pathway analysis.  
However, we particularly looked for 
genes involved in the regulation of 
hematopoiesis, cell cycle control, 
differentiation and apoptosis, where 
there was a baseline difference in gene 
expression between untreated NBM 
and MDS and where azacitidine 
treatment of MDS cells restored 
expression towards the level in NBM.  
We found three genes involved in the 
regulation of the P53 pathway, ATM, 
MDM2 and TP53BP1. Interestingly 
none of these showed promoter 
hypermethylation before azacitidine 
incubation, indicating that up-regulation 
was promoted by alternative 
mechanisms. Also others have reported 
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 a lack of correlation between changes 
in gene expression level after 
azacitidine and promoter methylation 
patterns pre-treatment.159
 
Our results, together with recent data 
from other groups, suggest that the 
mechanisms of azacitidine are complex, 
that they involve more than one cellular 
function and that they possibly are not 
related only to the DNA hypo-
methylating effects. Alternative 
mechanisms include histone 
modifications and inhibition of RNA 
methylation.159,160 
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 6 FUTURE PERSPECTIVES 
 
Until quite recently the therapeutic options for patients with myelodysplastic 
syndromes, especially those with high-risk disease were limited and prognosis was 
dismal. In the last decade both hypomethylating agents and lenalidomide have shown 
substantial positive effects and are used in routine clinical practice. Histone 
deacetylation inhibitors and thrombopoietin agonists are being evaluated in clinical 
trials with promising results. The exact mechanisms of action of these drugs are still 
not known, and are most probably complex. However, for hypomethylating agents and 
histone deacetylation inhibitors it is probable that they involve epigenetic modification. 
Future studies are warranted to elucidate their way of action in order to use the drugs 
in an optimal way in combination therapies and to be able to better select patients for 
the optimal treatment.  
Epigenetic changes in the MDS and AML stem cell will probably in the future be useful 
for prognostication and possibly also for the selection of therapy. However, 
standardization of techniques as well as a wider investigation of the patterns of 
epigenetic aberrations and their association with e.g. prognosis is necessary before 
this becomes a reality in the clinic. 
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 7 CONCLUSIONS 
 
Based on these studies it can be concluded that: 
 
• Hypermethylation of the E-cadherin promoter is associated with poor outcome 
of induction chemotherapy in high-risk myelodysplastic syndromes (MDS) and 
acute myeloid leukemia (AML) following MDS (MDS-AML). This finding, if 
reproduced in future studies, may have significant impact on study design as 
well as clinical management of patients with MDS. 
 
• Maintenance therapy with azacitidine after induction chemotherapy is feasible 
and has no negative effects on hemoglobin levels. 
 
• There is no clear effect of azacitidine maintenance after induction chemotherapy 
on duration of complete remission or overall survival, compared to historical 
materials. Some findings suggest a possible benefit in subgroups such as those 
with trisomy 8.  
 
• In de novo AML, hypermethylation of the P15ink4b promoter, as well as genome 
wide promoter hypermethylation, is associated with better disease-free survival 
and overall survival. However, global hypomethylation is associated with low 
complete remission rates. 
 
• Methylation patterns are of prognostic importance in both high-risk MDS/MDS-
AML and in de novo AML, but their prognostic value is completely different. This 
suggests that high-risk MDS/MDS-AML and de novo AML should be studied 
separately. 
 
• Azacitidine, also in high doses, has limited toxicity on normal bone marrow 
progenitors. In fact, clonogenic assays suggest a possible direct stimulatory 
effect of azacitidine on bone marrow progenitors. This supports the use of 
azacitidine maintenance after allogeneic stem cell transplantation to reduce the 
risk of relapse. 
 
• The intracellular effects of azacitidine are complex. Compared to cell line 
experiments, the drug induces less apoptosis and hypomethylation in primary 
MDS progenitors. Its effect on gene expression is strikingly different in MDS 
compared to normal bone marrow progenitors.  
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 8 SAMMANFATTNING  PÅ ENKEL 
SVENSKA 
 
Myelodysplastiskt syndrom (MDS) är en grupp av elakartade tumörsjukdomar som 
utgår från de blodbildande stamcellerna i benmärgen. MDS drabbar mellan 4 och 10 
av 100 000 invånare per år. Förekomsten ökar med stigande ålder. Medelåldern vid 
diagnos är ca 75 år och MDS är relativt ovanligt före 50 års ålder. Symtomen vid MDS 
är relaterade till brist på en eller flera typer av blodkroppar. Merparten av patienterna 
har uttalad brist på röda blodkroppar och det ger symtom som t.ex. trötthet, dålig 
kondition eller yrsel. Brist på blodplättar kan ge blödningsbesvär och brist på vita 
blodkroppar ger ökad risk för infektioner. Sjukdomsbilden varierar från långsamt 
tilltagande brist på blodkroppar och så småningom behov av blodtransfusioner (lågrisk-
MDS) till snabbt förlöpande sjukdom med övergång till akut myeloisk leukemi (AML) 
och död (högrisk-MDS).  
 
För att en normal cell ska övergå till att bli en cancercell krävs flera förändringar inne i 
cellen. Exakt vad som orsakar MDS är inte känt. En orsak kan vara uppkomst av fel på 
de blodbildande cellernas arvsmassa (genetiska fel). Detta yttrar sig bl.a. i 
kromosomavvikelser, t.ex. förlust av delar av eller hela kromosomer. Kromosomer 
finns i cellkärnan och är uppbyggda av tätt packat DNA, vår arvsmassa. Epigenetiska 
förändringar i cellen bidrar också. Detta innebär att själva DNA-sekvensen är 
oförändrad men uttrycket av olika gener ändå är ändrat. Detta kanske t.ex. genom att 
ökad mängd metylgrupper (små kemiska strukturer innehållande en kolatom och tre 
väteatomer) har kopplas till DNA i den del av en gen som reglerar om genen är aktiv 
eller inte, vilket stänger av genen (promotor hypermetylering). Aktiviteten av en gens 
uttryck kan också regleras av att DNA i kromosomen är olika hårt packat kring s.k. 
histonproteiner (histonmodifiering).  
 
För patienter med högrisk-MDS och de med tidigare MDS som övergått till AML (MDS-
AML) har det tills nyligen inte funnits några riktigt bra behandlingsalternativ eftersom 
de flesta patienter är för gamla för att tolerera höga doser av cellgifter eller allogen 
stamcellstransplantation, den enda potentiellt botande behandlingen vid MDS. Måttliga 
doser cellgifter kan tolereras relativt högt upp i åldrarna och har i flera studier visats 
kunna trycka tillbaka MDS-sjukdomen hos ca 50 % av patienter med högrisk-MDS. 
Problemet i samtliga dessa studier har dock varit att sjukdomen kommer snabbt 
tillbaka, oftast inom ett år. Någon effekt på överlevnad har inte kunnat visas på denna 
typ av behandling.  
 
Efter att stora studier visat god effekt, relativt lite biverkningar och förlängd överlevnad 
vid behandling av patienter med högrisk-MDS med läkemedlet azacytidin, blev detta 
läkemedel godkänt i USA 2004 och i Europa i början av 2009. Detta läkemedel anses 
verka på epigenetisk nivå. Dess exakta verkningsmekanism är inte känd men man vet 
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 att läkemedlet blockerar aktiviteten hos DNA metyltransferaser, enzymer som kopplar 
metylgrupper till DNA, och därigenom ger minskad DNA-metylering. En möjlig 
verkningsmekanism som föreslagits är att azacytidin tar bort felaktigt påkopplade 
metylgrupper från DNA och därigenom slår på felaktigt avstängda gener.  
 
I det första arbetet (Paper I) ville vi studera hur metyleringsmönstret av tre gener (P15, 
E-cadherin och HIC) relaterade till effekt av cellgiftsbehandling av patienter med 
högrisk-MDS eller MDS-AML. 60 patienter inkluderades i studien och behandlades 
med cellgifter. Vi tog prover från benmärgen före och efter behandlingen, dels för att 
kontrollera behandlingseffekt och dels för att studera metyleringsmönstret för de tre 
ovanstående generna. 24 patienter (40%) svarade på cellgifterna, d.v.s. man kunde 
inte längre se sjukdomen i benmärgen. Det viktigaste fyndet i den här studien var att 
patienter som hade ökad metylering av E-cadherin eller av mer än en av ovanstående 
gener hade mycket liten chans att svara på cellgiftsbehandlingen. Ingen av patienterna 
som hade ökad metylering på alla tre generna svarade. Denna studie var den första 
där ett sådant samband kunde visas. Detta innebär att man i framtiden möjligen bör 
kontrollera metyleringsmönstret hos patienter där man överväger cellgiftsbehandling 
och inte utsätta patienter med ökad metylering för sådan tuff behandling då deras 
chans att svara ändå är mycket liten. 
 
I det andra arbetet (Paper II) studerade vi effekten av att ge azacytidin till 23 patienter 
från ”Paper I” som svarat på cellgiftsbehandling med förhoppning att kunna förlänga 
den annars korta tiden till återfall. Denna studie var den första där azacytidin gavs på 
detta sätt. Behandlingen tolererades väl men medeltiden till återfall (13,5 månader) och 
medelöverlevnaden (20,0 månader) var tyvärr inte tydligt längre än i tidigare studier av 
cellgiftsbehandling utan efterföljande azacytidin i denna typ av patienter. En 
bidragande orsak kan möjligen vara att patienterna i vår studie var något äldre (medel 
68 år) än i de flesta tidigare studier. I vissa undergrupper, t.ex. de med 3 kopior av 
kromosom 8, sågs långvariga behandlingssvar men antalet sådana patienter var för få 
för att kunna dra säkra slutsatser. 
 
Efter att ha sett koppling mellan DNA-metyleringsmönster och effekt av 
cellgiftsbehandling i delarbete I ville vi studera om detta gällde också för patienter med 
akut leukemi utan tidigare blodsjukdom (de novo AML). I det tredje arbetet studerade vi 
metyleringsmönstret hos 107 sådana patienter. Till skillnad från i arbete I på 
MDS/MDS-AML såg vi ingen koppling mellan metylering av E-cadherin och prognos 
hos patienter med de novo AML. Däremot hade patienter med ökad metylering av P15 
bättre överlevnad. Ökad metylering av denna gen har i flera studier på MDS visat sig 
vara associerat med sämre prognos. Vi tittade också på metyleringsnivå över hela 
DNA, dvs. inte bara enstaka gener, och såg att patienter med låg grad av metylering 
svarade sämre på cellgiftsbehandling. Metyleringsmönster är således kopplat till 
prognos både vid högrisk-MDS/MDS-AML och vid de novo AML men betydelsen av 
förändringarna skiljer sig. I många studier på AML blandar man MDS-AML och de 
novo AML. Våra resultat pekar mot att de båda grupperna bör studeras separat. 
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 Målet med det sista arbetet (Paper IV) var att studera hur azacytidin påverkade 
benmärgsceller från patienter med högrisk-MDS och från friska individer för att på så 
sätt få bättre kunskap angående läkemedlets verkningsmekanismer. Vi odlade celler i 
laboratoriet och tillsatte azacytidin till flaskorna. Vi jämförde sedan obehandlade med 
azacytidinebehandlade benmärgsceller, både från MDS patienter och friska kontroller. 
Azacytidin visade sig ha förvånansvärt liten effekt på tillväxten av både MDS-celler och 
normala celler i odlingarna. När vi kontrollerade cellernas förmåga att bilda kolonier på 
odlingsplattor efter azacytidin-behandling sågs snarast ökad sådan förmåga.  Att 
läkemedlet verkar orsaka ganska liten skada på normala celler är viktig kunskap när 
man nu börjat använda azacytidin som behandling efter allogen 
stamcellstransplantation i syfte att minska risken för eller behandla återfall, en situation 
där man vill orsaka så liten skada som möjligt på de donerade friska cellerna. Vi såg 
viss generell minskning av DNA-metylering men den genspecifika metyleringen förblev 
oförändrad. Hur azacytidine påverkade uttrycket av 28 869 studerade gener varierade 
stort mellan MDS och normala celler. För ett fåtal särskilt intressanta gener där 
uttrycket ändrades av azacytidinbehandling kontrollerade vi också metylering. Samtliga 
var dock ometylerade redan innan azacytidinbehandlingen.  Slutsatsen blir att 
verkningsmekanismen för azacytidin sannolikt är komplex och inte enbart relaterad till 
DNA-metylering, utan också förändrar uttryck av gener genom andra mekansimer. 
 
 
    
 
 
 
 
 
 
 
 
 
 
 50
 9 ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude to everyone that either directly or indirectly 
contributed to this thesis, in particular to: 
 
Eva Hellström-Lindberg, my supervisor, for your enthusiasm and for acting as a 
counterbalance when my pessimistic side started to come out. Without that 
encouraging and cheerful attitude from you, I would have given up a long time ago. 
Thank you also for creating such a nice and merry atmosphere in the lab group. 
 
Jan Samuelsson, my co-supervisor, and his wife Maria, for really believing in me and 
supporting me in almost everything I do. Thank you Janne, for giving me the 
opportunity to do this, and thank you both for the many nice evenings and dinners, in 
Stockholm and abroad, where discussed topics many times have been related to 
things far from medicine and science. 
 
Lalla Forsblom and Monika Jansson, laboratory technicians in the MDS research 
group at Karolinska Huddinge, for teaching me all I know about working in a lab and for 
being a nice company during the many hours in the culture room and during many 
lunches and “fika”. Without you, my thesis and so many other theses never would have 
been possible. 
 
Patrik Andersson, Johan Andreasson, Mats Engström, Birgitta Goine, Maria 
Ljungqvist, Eva Ottosson and Kristina Sonnevi, my colleagues and friends at 
Södersjukhuset, for taking good care of my patients while I have been away in the lab. 
 
To all the nurses and assistant nurses at the ward and at the hematology daycare 
unit at Södersjukhuset for being positive and supportive (especially after a glass of 
wine – or two – outside the hospital of course) and for creating a nice environment to 
work in. 
 
Rasheed Khan, previous PhD student in the group, for teaching me the DGGE 
method and for being so enormously patient, even when I showed my grumpy side 
some late evenings after many work hours at the lab in Århus. Good luck with your 
clinical work! 
 
Mohsen Karimi, post-doc in the group, for your support and for sharing your 
knowledge on DNA-methylation and epigenetics with me. 
 
Stefan Deneberg and Sören Lehmann, for your collaboration to Paper III.  
 
 
 
 51
  
Martin Jädersten, Maryam Nikpour, Christian Scharenberg, Tobias Magnusson 
and AnQuan Lee fellow PhD students and post-doc, for your friendship and help and 
for creating a nice atmosphere in the group.  
 
All the members of the Nordic MDS Group, for your participation in the azacitidine 
maintenance study and for your feedback on and contribution to Paper I and II. 
 
Peter Hokland and Anni Aggerholm, at the department of hematology in Århus, for 
receiving me at your lab and teaching me the DGGE method. 
 
Hernán Concha and Alf Grandin for helping out with the FACS assays. 
 
Martin, Jonas, Christian, Johanna and Christel for still being good friends despite 
my absence these last 6 months or so. I hope that will change from now as this thesis  
finally is printed. 
 
Johan, Hanna and Anneli Berander, for many cups of tea and lots of “skorpor”, and 
for being an important part of my life during my teenage years. 
 
My parents, and to Patrick, Nichlas and Tobias, my brothers, for being a great family 
to grow up in and for always supporting me and showing that you are proud of me. 
 
Oscar, my partner and the most important person in my life, for making me feel loved. 
Thank you also for all your support during the work with this thesis. I will have to do a 
lot of cooking and washing to compensate. Maite zaitut! 
 
 
 
  
 
 
 
 
 
 
 
 52
 10 REFERENCES 
 
1.Rollison DE, Howlander N, Smith MT, Strom SS, Merrit WD, Ries LA, Edwards 
BK, and List AF. Epidemiology of myelodysplastic syndromes and chronic 
myeloproliferative disorders in the United States, 2001-2004, using data from 
the NAACCR and SEER programs. Blood 2008;112:45-52. 
2.Ma X, Does M, and Raza A. Myelodysplatic syndromes: Incidence and survival in 
the United States. Cancer 2007;109:1536-42. 
3.Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, García Costa A, Ros Forteza 
S, and Mayán Santos JM. Incidence and characteristics of myelodysplastic 
syndromes in Ourense (Spain) between 1994-1998. Haematologica 
2003;88:1197-9. 
4.Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, and Oscier DG. 
Establishing the incidence of myelodysplastic syndrome. Br J Haematol 
1994;84:743-5. 
5.Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R and Gattermann N. 
No increase in age-specific incidence of myelodysplastic syndromes. 
Haematologica 2004;89(8):905-10. 
6.Philips MJ, Cull GM, and Ewings M. Establishing the incidence of myelodysplastic 
syndrome. Br J Haematol 1994;84:896-7. 
7.Aul C, Gattermann N, and Schneider W. Age-related incidence and other 
epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 
1992;82:358-67. 
8.Pedersen-Bjergaard J, Christiansen DH, Andersen MK, and Skovby F. Causality 
of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. 
Leukemia 2002;16:2177-84. 
9.Descatha A, Jenabian A, Conso F, and Ameille J. Occupational exposures and 
haematological malignancies: overview on human recent data. Cancer Causes 
Control 2005;16:939-53. 
10.West RR, Stafford DA, Farrow A, and Jacobs A. Occupational and 
environmental exposures and myelodysplasia: a case-control study. Leukemia 
Res 1995;19(2):127-39. 
11.Strom SS, Gu Y, Gruschkus SK, Pierce SA, and Estey EH. Risk factors of 
myelodysplastic syndromes: a case-control study. Leukemia 2005;19(11):1912-
8. 
12.Grimwade DJ, Stephenson J, De Silva C, Dalton RG, and Mufti GJ. Familial 
MDS with 5q-abnormality. Br J Haematol 1993;84(3):536-8. 
13.Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, 
Vellespi T, Hamblin T, Oscier D, Ohayashiki K, Toyama K, Aul C, Mufti G, and 
Bennett J. International scoring system for evaluating prognosis in 
myelodysplastic syndromes. Blood 1997;89(6):2079-88. 
 53
 14.Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R and 
Leveque J. The incidence and impact of thrombocytopenia in myelodysplastic 
syndromes. Cancer 2007;109(9):1705-14. 
15.Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ and Machin D. Myelodysplastic 
syndromes: a scoring system with prognostic significance. Br J Haematol 
1985;59(3):425-33. 
16.Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabadella M, García S, Imguible 
D and San Miguel JF. Two regression models and a scoring system for 
predicting survival and planning treatment in myelodysplastic syndromes: a 
multivariate analysis of prognostic factors in 370 patients. Blood 
1989;74(1):395-408. 
17.Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, 
Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, and Cazzola M. 
Prognostic factors and life expectancy in myelodysplastic syndromes classified 
according to WHO criteria: A basis for clinical decision making. J Clin Oncol 
2005;23(30):7594-603. 
18.Mufti GJ, Figes A, Hamblin TJ, Oscier DG, and Copplestone JA. Immunological 
abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and 
autoantibodies. Br J Haematol 1986;63(1):143-7. 
19.Voulgarelis M, Giannouli S, Ritis K, and Tzioufas AG. Myelodysptasia-
associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin 
Invest 2004;34(10):690-700. 
20.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, and 
Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid 
tissues. Lyon IARC press 2008. 
21.Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 
2008;87(7):515-26. 
22.Mauritzon N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Björk J, 
Strömberg U, Nilsson PG, Mitelman F, Hagmar L, and Johansson B. Pooled 
analysis of clinical and cytogenetic features in treatment-related and de novo 
adult acute myeloid leukemia and myelodysplastic syndromes basted on a 
consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected 
cases reported in the literature 1974-2001. Leukemia 2002;16(12):2366-78. 
23.Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl 
Acad Sci USA 1971;68(4):820-23. 
24.Bacher U, Haferlach T, Kern W, Haferlach C and Schnittger S. A comparative 
study of molecular mutations in 381 patients with myelodysplastic syndrome 
and in 4130 patients with acute myeloid leukemia. Haematologica 
2007;92(6):744-52. 
25.Harada H, Harada Y, Niimi H, Kyo T, Kimura A and Inaba T. High incidence of 
somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and 
low blast percentage myeloid leukemia with myelodysplasia. Blood 
2004;103(6):2316-24. 
26.Zhang Y, Zhang M, Yang L and Xiao Z. NPM1 mutations in myelodysplastic 
syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 
2007;31(1):109-11. 
 54
 27.Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, Okada M, 
Mori N, Motoji T. Lack of nucleophosmin mutation in patients with 
myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 
abnormalities. Leuk Lymphoma 2007;48(11):2141-4. 
28.Steensma DP. The spectrum of molecular aberrations in myelodysplastic 
syndromes: in the shadow of acute myeloid leukemia. Haematologica 
2007;92(6):723-7. 
29.James C, Ugo V, LeCouédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, 
Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, 
Casadevall N and Vainchenker W. A unique clonal JAK2 mutation leading to 
constitutive signaling causes polycythemia vera. Nature 2005;434(7037):1144-
8. 
30.Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, 
Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliand DG, Lodish HF and 
Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic 
erythrocytosis. N Engl J Med 2007;356(5):459-68. 
31.Szpurka H, Tiu R, Murugesan G, Aboudola S, His ED, Theil KS, Sekeres MA 
and Maciejewski JP. Refractory anemia with ringed sideroblasts associated with 
marked thrombocytosis (RARS-T), another myeloproliferative condition 
characterized by JAK2 V617F mutation. Blood 2006;106(7):2173-81. 
32.Ingramn W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, Kiladjian JJ, 
Varkonyi J, Antunovic P, Westwood NB, Arno MJ, Mohamedali A, Gaken J, 
Kontou T, Czepulkowski BH, Twine NA, Tamaska J, Csomer J, Benedek S, 
Gattermann N, Zipperer E, Giagounidis A, Garcia-Casado Z, Sanz G and Mufti 
GJ. The JAK2 V617F mutation identifies a subgroup of MDS patients with 
isolated deletion 5q and a proliferative bone marrow. Leukemia 
2006;20(7):1319-21. 
33.Parker JE and Mufti GJ. The myelodysplastic syndromes: a matter of life and 
death. Acta Haematol 2004;111(1-2):78-99. 
34.Zang DY, Goodwin RG, LOken MR, Bryant E and Deeg HJ. Expression of tumor 
necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in 
myelodysplastic syndrome: effects on in vitro hematopoiesis. Blood 
2001;98(19):3058-65. 
35.Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, 
Gisselbrecht S, Mayeux and Dreyfus F. Ineffective erythropoiesis in 
myelodysplastic syndromes: correlation with FAS expression but not with lack of 
erythropoietin receptor signal transduction. Br J Haematol 1999;106(2):464-73. 
36.Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagiuca A and Mufti GJ. 
“Low-risk” myelodysplastic syndrome is associated with excessive apoptosis 
and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J 
Haematol 1998;103(4):1075-82. 
37.Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, 
Zhivotovsky B and Hellström-Lindberg E. Granulocyte colony-stimulating factor 
inhibits spontaneous cytochrome c release and mitochondria-dependent 
apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 
2003;101(3): 1080-6. 
 55
 38.Whibley C, Pharoah PD and Hollstein M. P53 polymorphisms: cancer 
implications. Nat Rev Cancer 2009;9(2):95-107. 
39.Petitjean A,Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M. TP53 
mutations in human cancers: functional selection and impact on cancer 
prognosis and outcome. Oncogene 2007;26(15):2157-65. 
40.Sugimoto K, Hirano N, Tooshima H, Chiba S, Mano H, Takaku F, Yazaki Y and 
Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and 
MDS-derived leukemia. Blood 1993;81(11):3022-6. 
41.Pedersen-Bjergaard J, Andersen MK, Andersen MT and Christiansen DH. 
Genetics of therapy-related myelodysplasia and acute myeloid leukemia. 
Leukemia 2008;22(2):240-8. 
42.Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J, Porwit 
A, Schlegelberger B and Hellström-Lindberg E. Clonal heterogeneity in the 5q- 
syndrome: p53 expressing progenitors prevail during lenalidomide treatment 
and expand at disease progression. Haematologica 2009;94(12):1762-6. 
43.Padua RA, Guinn BA, Al-Sabah Al, Smith M, Taylor C, Pettersson T, Ridge S, 
Carter G, White D, Oscier D, Chevret S and West R. RAS, FMS and P53 
mutations and poor clinical outcome in myelodysplasia: a 10-year follow-up. 
Leukemia 1998;12(6):87-92. 
44.Kita-Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, 
Nakagawa H, Fujii H and Taniwaki M. International prognostic scoring system 
and TP53 mutations are independent prognostic indicators for patients with 
myelodysplastic syndrome. Br J Haematol 2001;115(2):309-12. 
45.Baumann I, Scheid C, Koref MS, Swindell R, Stern P and Testa NG. Autologous 
lymphocytes inhibit hematopoiesis in long-term culture in patients with 
myelodysplastic syndrome. Exp hematol 2002;30(12):1405-11. 
46.Ruggiero G, Sica M, Luciano L, Savioia F, Cosentini E, Alfinito F and 
Terrazzano G. A case of myelodysplastic syndrome associated with CD14(+) 
CD56(+) monocytosis, expansion of NK lymphocytes and defect o HLA-E 
expression. Leuk Res 2009;33(1):181-5. 
47.Sloand  EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar 
K, Lu J, Basu A, Baret AJ, and Young NS. Preferential suppression of trisomy I 
compared with normal hematpoietic cell growth by autologous lymphocytes in 
patients with trisomy 8 myelodysplastic syndrome. Blood 2005;106(3):841-51. 
48.Maciejewski JP, O’Keefe C, Gondek L and Tiu R. Immune-mediated bone 
marrow failure syndromes of progenitor and stem cells: molecular analysis of 
cytotoxic T cell clones. Folia Histochem Cytobiol 2007;45(1):5-14. 
49.Kochenderfer JN, Kobayashi S, Wieder E, Su C and Molldrem JJ. Loss of T-
lymphocyte clonal dominance in patients with myelodysplastic syndrome 
responsive to immunosuppression. Blood 2002;100(10):3639-45. 
50.Matsutani T, Yoshioka T, Tsuruta Y, Shimamoto T, Ohyashiki JH, Suzuki R and 
Ohyashiki K. Determination of T-cell receptors of clonal CD8-positive T-cells in 
myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003;27(4):305-
12. 
51.Wilson A and Trumpp A. Bone-marrow haematopoietic stem cell niches. Nat 
Rev Immunol 2006;6(2):93-106. 
 56
 52.Varga G, Kiss J, Várkonyi J, Vas V, Farkas P, Pálóczi K and Uher F. 
Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the 
bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 
2007;13(4):311-9. 
53.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, and 
Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br 
J Haematol 1982;51(2):189-99. 
54.Malcovati L, Germing U, Kündgen A, Della Porta MG, Pascutto C, Invernizzi R, 
Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, 
Aul C and Cazzola M. Time-dependent prognostic scoring system for predicting 
survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 
2007;25(23):3503-10 
55.Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, 
Passamonti F, Invernizzi R, Castell A, Magrini U, Lazzarino M and Cazzola M. 
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in 
primary myelodysplastic syndromes. J Clin Oncol 2009;27(5):754-62. 
56.Harper P and Littlewood T. Anaemia of cancer: impact on patient fatigue and 
long-term outcome. Oncology 2005;69,Suppl 2: 2-7. 
57.Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, 
Slavin MB and Glasmpy JA. Relationship between changes in hemoglobin level 
and quality of life during chemotherapy in anemic cancer patients receiving 
epoetin alfa therapy. Cancer 2002;95(4):888-95. 
58.Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal 
I, Grimfors G, Hesse-Sundin E, Thorth M, Kanter-Lewensohn L,  
Linder O, Luthman M, Löfvenberg E, Öberg G, Porwit-MacDonald A,       
Rådlund A, Samuelsson J, Tangen JM, Winquist I and Wisoff F. A validated 
decision model for treating the anaemia of myelodysplastic syndromes with 
erythropoietin + granulocyte colony-stimulating factor: significant effects on 
quality of life. Br J Haematol 2003;120(6):1037-46. 
59.Telfer P. Update on survival in thalassemia major. Hemoglobin 2009;33 Suppl 
1:S76-80. 
60.Taher AT, Musallam KM and Inati A. Iron overload: Consequences, 
assessment, and monitoring. Hemoglobin 2009;33 Suppl 1: S46-57. 
61.Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, 
Allen CJ, Farrell DE and Harris JW. Efficacy of deferoxamine in preventing 
complications of iron overload in patients with thalassemia major. N Engl J Med 
1994;331(9):567-73. 
62.Oliva EN, Ronco F, Marino A, Alati C, Praticò G and Nobile F. Iron chelation 
therapy associated with improvement of hematopoiesis in transfusion-
dependent patients. Transfusion 2010;50(7):1568-70. 
63.Messa E, Cilloni D, Messa F, Arruga F, Roetto A and Saglio G. Deferasirox 
treatment improved the hemoglobin level and decreased transfusion 
requirements in four patients with the myelodysplastic syndrome and primary 
myelofibrosis. Acta Haematol 2008;120(2):70-4. 
64.Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa 
D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P and 
 57
 Fenaux P. Does iron chelation therapy improve survival in regularly transfused 
lower risk MDS patients? A multicenter study by the GFM (Groupe 
Francophone des Myélodysplasies). Leuk Res 2010;34(7):864-70. 
65.Gatterman N. Overview of guidelines on iron chelation therapy in patients with 
myelodysplastic syndromes and transfusional iron overload. Int J Hematol 
2008;88(1):24-9. 
66.Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ and Antin 
JH. Prognositc impact of elevated pretransplantation serum ferritin in patients 
undergoing myeloablative stem cell transplantation. Blood 2007;109(10):4586-
8. 
67.Lim ZY, Fiaccadori V, Gandhi S, Hayden J, Kenyon M, Ireland R, Marsh J, Ho 
AY, Mifti GJ and Pagliuca A. Impact of pre-transplant serum ferritin on 
outcomes of patients with myelodysplastic syndromes or secondary acute 
myeloid leukaemia receiving reduced intensity conditioning allogeneic 
haematopoietic stem cell transplantation. Leuk Res 2010;34(6):723-7. 
68.Alessandrino EP, Della Porta MG, Baciaglupo A, Malcovati L, Angelucci E, Van 
Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, 
Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R and 
Bosi A. Prognostic impact of pre-transplantation transfusion history and 
secondary iron overload in patients with myelodysplastic syndrome undergoing 
allogeneic stem cell transplantation: a GITMO study. Haematologica 
2010;95(3):476-84. 
69.Moyo V, Lefebre P, Duh MS, Yektashenas B and Mundle S. Erythropoiesis-
stimmulating agents in the treatment of anemia in myelodysplastic syndromes: 
a meta-analysis. Ann Hematol 2008;87(7):527-36. 
70.Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic 
syndromes: a meta-analysis of 205 patients from 17 studies. B J Haematol 
1995;89(1):67-71. 
71.Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R and Hellström-Lindberg 
E. The WHO classification of MDS does make difference. Blood 
2004;103(9):3265-70. 
72.Hellström-Lindberg E, Ahlgren T, Beguin Y, Carsson M, Carneskog J, Dahl IM, 
Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg 
E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Öberg G, Österborg 
A and Öst Å. Treatment of anemia in myelodysplastic syndromes with 
granulocyte colony-stimulating factor plus erythropoietin: results from a 
randomized phase II study and long-term follow-up of 71 patients. Blood 
1998;92(1):68-75. 
73.Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, Damaj 
G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, 
Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F and 
Fenaux P. Health, economi, and quality-of-life effects of erythropoietin and 
granulocyte colony-stimulating factor for the treatment of myelodysplastic 
syndromes: a randomized controlled trial. Blood 2004;104(2):321-7. 
74.Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, 
Spriano M, Timitilli S and Ghio R. Erythropoietin plus granulocyte colony-
 58
 stimulating factor is better than erythropoieting alone to treat anemia in low-risk 
myelodysplastic syndromes: results from a randomized single-center study. Ann 
Hematol 2006;85(3):174-80. 
75.Hellström-Lindberg E, Guldbrandsen N, Lindberg G, Ahlgren T, Dahl IM, 
Dybedal I,Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder 
O, Luthman M, Löfvenberg E, Öberg G, Porwit-MacDonald A, Rådlund A, 
Samuelsson J, Tangen JM, Winquist I, Wisloff F; Scandinavian MDS Group. A 
validated decision model for treating the aneaemia of myelodysplastic 
syndromes with erythropoietin + granulocyte colony-stimulating factor: 
significant effects on quality of life. Br J Haematol 2003;120(6):1037-46. 
76.Rigolin GM, Porta MD, Ciccone M, Bugli AM, Bragotti LZ, Mauro E, Fraulini C, 
Rossi AR, Bardi A, Cuneo A and Castoldi G. In patients with myelodysplastic 
syndromes response to rHuEPO and G-CSF treatment is related to an increase 
of cytogenetically normal CD34 cells. Br J Haematol 2004;126(4):501-7. 
77.Ljung T, Bäck R and Hellström-Lindberg E. Hypochromic red blood cells in low-
risk myelodysplastic syndromes: effects of treatment with hematopoietic growth 
factors. Haematologica 2004;89(12):1446-53. 
78.Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, Marsh J 
and Mufit GJ. Low IPSS score and bone marrow hypocellularity in MDS patients 
predict hematological responses to antithymocyte globulin. Leukemia 
2007;21(7): 1436-41. 
79.Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, Porwit-
MacDonald A, Sjöö M, Tangen JM, Uggla B, Öberg G and Hellström-Lindberg 
E. Antithymocyte globulin and cyclosporine A as a combination therapy for low-
risk non-sideroblastic myelodysplastic syndromes. Haematologica 
2006;91(5):667-70. 
80.Sloand EM, Wu CO, Greenberg P, Young N and Barret J. Factors affecting 
response and survival in patients with myelodysplasia treated with 
immunosuppressive therapy. J Clin Oncol 2008;26(15):2505-11. 
81.Killick SB, Mufti GJ, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, 
Bowen DT and Marsh JC. A pilot study of antithymocyte globulin (ATG) in the 
treatment of patients with “low-risk” myelodysplasia. B J Haematol 
2003;120(4):679-84. 
82.List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, 
Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, 
Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study investigators. 
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.  
N Engl J Med 2006;355(14):1456-65. 
83.Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, 
Åstrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, 
Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-
Lindberg E, List A, Nilsson L and Jacobsen SE. Persisten malignant stem cells 
in del(5q) myelodysplasia in remission. N Engl J Med 2010;363(11):1025-37. 
84.Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, 
Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, 
Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB and List 
 59
 AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and 
intermediate-1 risk myelodysplastic syndromes with karyotypes other than 
deletion 5q. Blood 2008;111(1):86-93. 
85.Adès L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C, Dreyfus F, 
Stamatoullas A, Chaury MP, Delaunay J, Laurent G, Vey N, Burcheri S, Mbida 
RM, Hoarau N, Gardin C and Fenaux P. Efficacy and safety of lenalidomide in 
intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results 
of a phase II study. Blood 2009;113(17):3947-52. 
86.Möllgård L, Nilsson L, Kjeldsen L, Dybedal I, HoghDufva I, Garelius H, Maxwell 
Norgaard J, Linder O, Ejerblad E, Astermark J and Hellström-Lindberg E. 
Lenalidomide in high-risk myelodysplastic syndrome and acute myeloid 
leukemia with chromosome 5 abnormalities. Blood (ASH Annual Meeting 
Abstracts) 2009;114(22):115 
87.Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-
Lindberg E, Aul C and Schlegelberger B. Patients with del(5q) MDS who fail to 
achieve sustained erythroid or cytogenetic remission after treatment with 
lenalidomide have an increased risk for clondal evolution and AML progression. 
Ann Hematol 2010;89(4):365-74. 
88.Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J, Porwit 
A, Sclegelberger B and Hellström-Lindberg E. Clonal heterogeneity in the 5q- 
syndrome: P53 expressing progenitors prevail during lenalidomide treatment 
and expand at disease progression. Haematologica 2009;94(12):1762-6. 
89.Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus RD, Vukov 
A, Li CY, Menke DM, Geyer SM and Alberts SR; North Central Cancer 
Treatment Group. Thalidomide therapy in adult patients with myelodysplastic 
syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 
2006;107(4):767-72. 
90.Bouscary D, Legros L, Tulliez M, Dubois, S, Mahe B, Beyne-Rauzy O, Quarre 
MC, Vassilief D, Varet B, Aouba A, Gardemabs M, Giraudier S, Guerci A, 
Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P and 
Dreyfus F. A non-randomized dose escalating phase II study of thalidomide for 
the treatment of patients with low-risk myelodysplastic syndromes: the Thal-
SMD-2000 trial of the Group Français des Myélodysplasies. Br J Haematol 
2005;131(5):609-18. 
91.Bartlett JB, Dredge K and Dalgleish AG. The evolution of thalidomide and its 
IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314-22. 
92.Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, 
Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, 
Boultwood J and Hellström-Lindberg E. Lenalidomide inhibits the malignant 
clone and up-regulates the SPARC gene mapping to the commonly deletied 
region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104(27):11406-
11. 
93.Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili Naomi, Raza A, Root 
DE, Attar E, Ellis SR and Golub TR. Identification of RPS14 as a 5q- syndrome 
gene by RNA interference screen.Nature 2008;451(7176):335-9. 
 60
 94.Oliva EN, Cuzzola M, Nobile F, Ronco F, D’Errigo MG, Laganà C, Morabito F, 
Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Brecia M, 
Ghio R, Finelli C, Iacopino P, Alimena G and Latagliata R. Changes in RPS14 
expression levels during lenalidomide treatment in Low-and Intermediate-1-risk 
myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 
2010;85(3):231-5. 
95.Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahé B, 
Couteaux ME, Resegotti L, Voglova V, Foussard C, Pegourié B, Michaux JL, 
Deconinck E, Stoppa AM, Mufti GJ, Oscier D and Fenaux P. A randomized trial 
of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe 
Français des Myélodysplasies and European CMML Group. Blood 
1996;88(7):2480-7. 
96.Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, 
Cassileth PA and O’Connell MJ. The evaluation of low-dose cytarabine in the 
treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann 
Hematol 1992;65(4):162-8. 
97.Hellström-Lindberg E, Robert KH, Gahrton G, Lindberg G, Forsblom AM, Kock 
Y and Öst Å. A predictive model for the clinical response to low dose ara-C: a 
study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J 
Haematol 1992;81(4):503-11. 
98.De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic 
B, Selleslag D, Zittoun R and Dardenne M. Intensive chemotherapy for poor 
prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia 
(sAML) following MDS of more than 6 months duration. A pilot study by the 
Leukemia Cooperative Group of the European Organization for Research and 
Treatment in Cancer (EORTC-LCG). Leukemia 1995;9(11):1805-11. 
99.Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, 
Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L and 
Hoetzer D. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-
AMSA followed by immunotherapy with interleukin-2 for myelodysplastic 
syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol 
2000;79(1):30-5. 
100.Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, 
Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, 
Westerhausen M, Koelbel CB, Hoetzer D and Ganser A. Intensive 
chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in 
patients with advanced myelodysplastic syndrome and high-risk acute myeloid 
leukemia. Ann Hematol 2004:83(8):498-503. 
101.Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero 
G, Wierda W, Pierce S, Shan J and Estey E. Results of intensive chemotherapy 
in 998 patients age 65 years or older with acute myeloid leukemia or high-risk 
myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 
2006:106(5):1090-8. 
102.Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, 
Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Hilsson-
Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, 
 61
 Wallvik J, Winquist I, Öberg G and Bernell P. No benefit fron adding GM-CSF to 
induction chemotherapy in transforming myelodysplastic syndromes: better 
outcome in patients with less proliferative disease. Leukemia 2003;17(9):1827-
33. 
103.Kantarjian H, Beran M, Cortes J, O’Brien S, Giles F, Pierce S, Shan J, Plunkett 
W, Keating M and Estey E. Long-term follow-up results of the combination of 
topotecan and cytarabine and other intensive chemotherapy regimens in 
myelodysplastic syndrome. Cancer 2006;106(5):1099-109. 
104.Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, 
Aul C, Fière D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, 
Cortes J, de Witte T and Estey E; EORTC, EBMT, SAKK, GIMEMA Leukemia 
Groups and the MD Anderson Cancer Center. Chemotherapy only compared to 
chemotherapy followed by transplantation in high-risk myelodysplastic 
syndrome and secondary acute myeloid leukemia; two parallel studies adjusted 
for various prognostic factors. Leukemia 2002;16(9):1615-21. 
105.De Witte T, Hagenmeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, 
Selleslag D, Schouten H, Ferrant A, Berisack H, Amadori S, Muus P, Jansen 
JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, 
Gratwohl A, Marie JP and Willemze R. Value of allogeneic stem cell 
transplantation versus autologous stem cell transplantation and chemotherapy 
in patients with myelodysplastic syndromes and secondary acute myeloid 
leukemia: a prospective randomized European intergroup trial. Haematologica 
2010;[Epub ahead of print] 
106.Marcondes M and Deeg HJ. Hematopoietic cell transplantation for patients with 
myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res 
Clin Haematol 2008;21(1):67-77. 
107.Storb R. Reduced-intensity conditioning transplantation in myeloid 
malignancies. Curr Opin Oncol 2009;21 Suppl 1:S3-5. 
108.Lim Z, Brand R, Martino R, van Biezen A, Finke J, Baciagalupo A, Beelen D, 
Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet 
JP, Niederwieser D, Kroger N, Mufti GJ and de Witte T. Allogeneic 
hematopoietic stem-cell transplantation for patients 50 years or older with 
myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 
2010;28(3):405-11. 
109.Warlick ED, Cioc A, Defor T, Dolan M and Weisdorf D. Allogeneic stem cell 
transplantation for adults with myelodysplastic syndromes: importance of 
pretransplant disease burden. Biol Blood Marrow Transplant 2009;15(1):30-8. 
110.De Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, von dem Borne 
P, Vitek A, Delforge M, Alessandrino P, Harlahakis N, Russell N, Martino R, 
Verdonck L, Kröger N and Niederwieser D. European Blood and Marrow 
Transplantation Group (EBMT) Chronoic Leukemia Working Party (CLWP)-
MDS subcommittee. Allogeneic stem cell transplantation for patients with 
refractory anaemia with matched related and unrelated donors: delay of the 
transplant is associated with inferior survival. Br J Haematol 2009;146(6):627-
36. 
 62
 111.Deschler B and Lübbert M. Acute myeloid leukemia: epidemiology and 
etiology. Cancer 2006;107(9):2099-107. 
112.Ferrara F. Acute promyelocytic leukemia: what are the treatment options? 
Expert Opin Pharmacother 2010;11(4):587-96. 
113.Rowe JM. Optimal induction and post-remission therapy for AML in first 
remission. Hematology Am Soc Hematol Educ Program 2009:396-405. 
114.Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G, Harrison 
CH, Goldstone A and Burnett A; NCRI Adult Leukaemia Working Party. Impact 
of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol 
2004;83 Suppl 1:S45-8. 
115.Stone RM. Prognostic factors in AML in relation to (ab)normal karyotype. Best 
Pract Res Clin Hematol 2009;22(4):523-8. 
116.Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, 
Dombret H, Fenaux P, Grimwalde D, Larson RA, LoCoco F, Naoe T, 
Niederwieser D, Ossen koppele GJ, Sanz MA, Sierra J, Tallman MS, 
Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and 
management of acute meloid leukemia in adults: recommendations from an 
international expert panel, on behalf of the European LeukemiaNet. Blood 
2010;115(3):453-74. 
117.Reik W. Stability and flexibility of epigenetic gene regulation in mammalian 
development. Nature 2007;447(7143):425-32. 
118.Li E. Chromatin modification and epigenetic reprogramming in mammalian 
development. Nat Rev Genet 2002;3(9):662-73. 
119.Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59. 
120.Turek-Plewa J and Jagodziński PP. The role of mammalian DNA 
methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 
2005;10(4):631-47. 
121.Bird AP. CpG-rich islands and the function of DNA methylation. Nature 
1986;321(6067):209-13. 
122.Singal R and Ginder GD. DNA methylation. Blood 1999;93(12):4059-70. 
123.Goll MG and Bestor TH. Eurkaryotic cytosine methyltransferases. Annu Rev 
Biochem 2005;74;481-514. 
124.Goll MG, Kirpekar F, MAggert KA, Yoder JA, Hsieh CL, Zhang X, Golic KG, 
Jacobsen SE and Bestor TH. Methylation of tRNAAsp by the DNA 
methyltransferase homolog DNMT2. Science 2006;311(5759):395-8. 
125.Felsenfeld G and Groudine M. Controlling the double helix. Nature 
2003;421(6921):448-53. 
126.Bhaumik SR, Smith E and Shilatifard A. Covalent modifications of histones 
during development and disease pathogenesis. Nat Struct Mol Biol 
2007;14(11):1008-16. 
127.Marmorstein R and Roth SY. Histone acetyltransferases: function, structure, 
and catalysis. Curr Opin Genet Dev 2001;11(2):155-61. 
128.Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello C. Potent and 
specific genetic interference by double stranded RNA in canorhabditis elegans. 
Nature 1998;391:6669:806-11. 
 63
 129.Kurreck J. RNA interference: from basic research to therapeutic implications. 
Angew Chem Int Ed Engl 2009;48(8):1378-98. 
130.Feinberg AP, Ohlsson R and Henikoff S. The epigenetic progenitor origin of 
human cancer. Nat Rev Genet 2006;7(1):21-33. 
131.Lehmann U, Brakensiek K and Kreipe H. Role of epigenetic chances in 
hematological malignancies. Ann Hematol 2004;83(3):137-52. 
132.Egger G, Liang G, Aparicio A and Jones PA. Epigenetics in human disease 
and prospects for epigenetic therapy. Nature 2004;429(6990):457-63. 
133.Costelllo JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, 
Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield 
CD, Caligiuri MA, Yates A, Hishikawa R, Su Huang H, Petrelli NJ, Zhang X, 
O’Dorisio MS, Held WA, Cavenee WK and Plass C. Aberrant CpG-island 
methylation has non-random and tumour-type-specific patterns. Nat Genet 
2000;24(2):132-8. 
134.Esteller M, Corn PG, Baylin SB and Herman JG. A gene hypermethylation 
profile of human cancers. Cancer Res 2001;61(8):3225-9 
135.Mahlknechts U and Hoeltzer D. Histone acetylation modifiers in the 
pathogenesis of malignant disease. Mol Med 2000;6(8):623-44. 
136.Somech A, Izraeli S and Simon J. Histone deacetylase inhibitors – a new tool 
to treat cancer. Cancer Treat Rev 2004;30(5):461-72. 
137.Aggerholm A, Holm MS, Guldberg P, Olesen LH and Hokland P. Promoter 
hypermethylation of P15INK4b, HIC1, CDH1 and ER is frequent in 
myelodysplastic syndrome and predicts poor prognosis in early-stage patients. 
Eur J Haematol 2006;76(1):23-32. 
138.Melki JR, Vincent PC and Clark SJ. Concurrent DNA hypermethylation of 
multiple genes in acute myeloid leukemia. Cancer Res 1999;59(15):3730-40. 
139.Figueroa ME, Skrabanek L, Li Y, Jiemijit A, Fandy TE, Paietta E, Fernandez H, 
Tallman MS, Greally JM, Caraway H, Licht JD, Gore SD and Melnick A. MDS 
and secondary AML display unique patterns and abundance of aberrant DNA 
methylation. Blood 2009;114(16):3448-58. 
140.Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O’Keefe C, Sekeres M, 
Saunthararajah Y and Maciejewski JP. Aberrant DNA methylation is a dominant 
mechanism in MDS progression towards AML. Blood 2009;113(6):1315-25. 
141.Kim M, Oh B, Kim SY, Hwang SM, Kim TY, She CJ, Yang I, Yoon SS, Yoon 
JH and Lee DS. P15ink4b methylation correlates with thrombocytopenia, blast 
percentage, and survival in myelodysplastic syndromes in a dose dependent 
manner: quantitation using pyrosequencing study. Leuk Res 2010;34(6):718-22 
142.Christiansen DH, Andersen MK and Pedersen-Bjergaard J. Methylation of 
P15ink4b is common, is associated with deletion of genes on chromosome arm 
7q and predicts a poor prognosis in therapy-related myelodysplastia and acute 
myeloid leukemia. Leukemia 2003;17(9):1813-19. 
143.Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC and Shen 
MC. Methylation of the P15(ink4b) gene in myelodysplastic syndrome: it can be 
detected early at diagnosis or during disease progression and is highly 
associated with leukemic transformation. Br J Haematol 2001;112(1):148-54. 
 64
 144.Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, 
Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, 
Öberg G, Jacobsen SE, Hokland P, Porwit A and Hellström-Lindberg E. 
Negative effect of DNA hypermethylation on the outcome of intensive induction 
chemotherapy in older patients with high-risk myelodysplastic syndromes and 
acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 
2007;12(23):7107-12. 
145.Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK and Issa 
JP. Estrogen receptor methylation is associated with improved survival in adult 
myeloid leukemia. Clin Cancer Res 1999;5(5):1077-84. 
146.Shimamoto T, Ohyashiki JH and Ohyashiki K. Methylation of P15(ink4b) and 
E-cadherin genes is independently correlated with poor prognosis in acute 
myeloid leukemia. Leuk Res 2001;29(6):654-9. 
147.Chim CS, Tam CY, Liang R, Kwong YL. Methylation of P15 and P16 genes in 
adult acute leukemia: lack of prognostic significance. Cancer 2001;91(12):2222-
9. 
148.Galm O, Wilop S, Lüders C, Jost E, Gehbauer G, Herman JG and Osieka R. 
Clinical implication of aberrant DNA methylation patterns in acute myelogenous 
leukemia. Ann Hematol 2005;84 Suppl 1:39-46. 
149.Wong IH, Huang DP and Lee JC. Aberrant P15 promoter methylation in adult 
and childhood acute leukemias of nearly all morphologic subtypes: potential 
prognostic implications. Blood 2000;95(6):1942-9. 
150.Olesen LH, Aggerholm A, Andersen BL, Nyvold CG, Guldberg P, Nørgaard JM 
and Hokland P. Molecular typing of adult acute myeloid leukemia: significance 
of translocations, tandem duplications, methylation, and selective gene 
expression. Br J Haematol 2005;131(4):457-67. 
151.Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbahioglu A, Gaidzik 
V, Döhner K, Paul C, Ekström TJ, Hellström-Lindberg E and Lehmann S. Gene-
specific and global methylation patterns predict outcome in patients with acute 
myeloid leukemia. Leukemia 2010;24(5):932-41. 
152.O’Dwyer K and Maslak P. Azacitidine and the beginnings of therapeutic 
epigenetic modulation. Expert Opin Pharmacother 2008;9(11):1881-6. 
153.Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of 
hematologic malignancies. J Clin Oncol 2005;23(17):3971-93. 
154.Khan R, Aggerholm A, Hokland P, Hassan M and Hellström-Lindberg E. A 
pharmacodynamic study of 5-azacytidine in the P39 cell line. Exp Hematol 
2006:34(1):35-43. 
155.Schmeltz K, Sattler N, Wagner M, Lübbert M, Dörken B and Tamm I. 
Inductions of gene expression by 5-aza-2’-deoxycytidine in acute myeloid 
leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by 
DNA-methylation dependent and independent mechanisms. Leukemia 
2005;19(1):103-11. 
156.Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ, 
Zhivotovsky B and Hellström-Lindberg E. Hypomethylation and apoptosis in 5-
azacytidine-treated myeloid cells. Exp Hematol 2008;36(2):149-57. 
 65
 157.Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, 
Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, 
González FJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF and 
Pérez-Simon JA. Immunomodulatory effect of 5-azacytidine (5-azaC): potential 
role in the transplantation setting. Blood 2010;107-21. 
158.Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA and Di Fiore PP. 5-aza-2’-
deoxycytidine induces terminal differentiation of leukemic blasts from patients 
with acute myeloid leukemias. Blood 1984;64(4):922-9. 
159.Komsashko VM and Farnham PJ. 5-azacytidine treatment reorganizes 
genomic histone modification patterns. Epigenetics 2010;5(3):[Epub ahead of 
print] 
160.Schaefer M, Hagemann S, Hanna K and Lyko F. Azacytidine inhibits RNA 
methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 
2009;69(20):8127-32. 
161.Guo Y, Engelhardt M, Wider D, Abdelkarim M and Lübbert M. Effects of 5-aza-
2’-deoxycitidine on proliferation, differentiation and P15ink4b regulation of 
human hematopoietic progenitor cells. Leukemia 2006;20(1):115-21. 
162.Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E 
and Lübbert M. The DNA demethylating agent 5-aza-2’’deoxycytidine induces 
expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia 
cells. Leuk Res 2010;34(7):899-905 
163.Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, 
Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P and Craddock C. Induction 
of a CD8+ T-cell response to the MAGE cancer testis antigen by combined 
treatment with azacitidine and sodium valproate in patients with acute myeloid 
leukemia and myelodysplasia. Blood 2010;116(11):1908-18. 
164.Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, 
Odchimar-Reissig R, Stone RM, Nelston D, Powell BL, DeCastro CM, Ellerton 
J, Larson RA, Schiffer CA and Holland JF. Randomized controlled trial of 
azacitidine in patients with the myelodysplastic syndrome: a study of the cancer 
and leukemia group B. J Clin Oncol 2002;20(10):2429-40 
165.Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A, 
Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennet JM, 
Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; 
International Vidaza High-Risk MDS Survival Study Group. Efficacy of 
azacitidine compared with that of conventional care regimens in the treatment of 
higher-risk myelodysplastic syndromes: a randomized, open-label, phase III 
study. Lancet Oncol 2009;10(3):223-32. 
166.Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing 
U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman 
L, McKenzie D, Beach CL and Silverman LR. Azacitidine prolongs survival 
compared with conventional care regimens in elderly patients with low bone 
marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9. 
167.Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini 
V, List AF, Gore SD, Backstrom J, McKenzie D and Beach CL. Effects of 
azacitidine compared with conventional care regimens in elderly (>/=75 years) 
 66
 patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 
2010;[Epub ahead of print] 
168.Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, 
McIntyre HJ, Fernando IJ, Backstrom JT and Beach CL. Hematologic response 
to three alternative dosing schedules of azacitidine in patients with 
myelodysplastic syndromes. J Clin Oncol 2009;27(11):1850-6. 
169.Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, 
Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group 
on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Azacitidine for 
the treatment of lower risk myelodysplastic syndromes: a retrospective study on 
74 patients enrolled in an Italian named patient program. Cancer 
2010;116(11):1485-94. 
170.Kantarjian H, Issa JP, Rosenfeld CS, Bennet JM, Albitar M, DiPersio J, Klimek 
V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Limer SD, Leavitt R, 
Raza A and Saba H. Decitabine improves patient outcomes in myelodysplastic 
syndromes. Results of a phase III randomized study. Cancer 2006;106(8):1794-
803. 
171.Wijermans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D, 
Labar B, Salih H, Beeldens F, Muus P, de Witte T and Lübbert M. Low dose 
decitabine versus best supportive care in elderly patients with intermediate or 
high risk MDS not eligible for intensive chemotherapy: final results of the 
randomized pahse III study (06011) of the EORTC Leukemia and German MDS 
Study Groups. Blood (Annual Meeting Abstracts) 2008;112:226. 
172.List AF, Fenaux O, Mufti GJ, Hellström-Lindberg E, Gore S, Bennett JM, 
Silverman LR, Backstrom J, Allen AR and Beach CL. Effect of azacitidine (AZA) 
on overall survival in higher-risk myelodysplastic syndromes (MDS) without 
complete remission. J Clin Oncol 2008;26:abstr 7006. 
173.Raj K, John A, Ho A, Chronis C, Khan S, Sameul J, Pomplun S, Thomas NS 
and Mufti GJ. CDKN2b methylation status and isolated chromosome 7 
abnormalities predict responses to treatment with 5-azacitidine. Leukemia 
2007;21(9):1937-44. 
174.Yang AS, Doshi KD, Choi SW, Mason JB, MAnnari RK, Ghaybian V, Luna R, 
Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G and Issa JP. 
DNA methylation changes after 5-aza-2’-deoxycytidine therapy in patients with 
leukemia. Cancer Res 2006;66(10):5495-503. 
175.Lübbert M, Bertz H, Rüter B, Marks R, Claus R, Wäsch R and Finke J. Non-
intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to 
allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 
2009;44(9):585-8. 
176.Cogle CR, Imanirad I, Wiggins LE, Hsu J, Bronwn R, Scornik JC and Wingard 
JR. Hyopmethylating agent induction therapy followed by hematopoietic cell 
transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv 
Hematol Oncol 2010;8(1):40-6. 
177.Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de 
Padua L, Shpall EJ, Champlin R and de Lima M. Low-dose azacitidine after 
 67
 allogeneic stem cell transplantation for acute leukemia. Cancer 
2009;115(9):1899-905. 
178.Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, 
Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A and Anasetti 
C. 5-azacitidine for myelodysplasia before allogeneic hematopoietic cell 
transplantation. Bone Marrow Transplant 2010;45(2):255-60. 
179.Ravandi F, Kantarjian H, Cohen A, Davis M, O’Brien S, Anderlini P, Andersson 
B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, 
Champlin R and Giralt S. Decitabine with allogeneic peripheral blood stem cell 
transplantation in the therapy of leukemia relapse following a prior transplant: 
results of a phase I study. Bone Marrow Transplant 2001;27(12):1221-5. 
180.Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, 
Paulic K, Afable M, Saba HI, Loughran TP Jr and Maciejewski JP. Phase I 
combination trial of lenalidomide and azacitidine in patients with higher-risk 
myelodysplastic syndromes. J Clin Oncol 2010;28(13):2253-8. 
181.Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, 
Rychlik K, Germano E and Stiff P. Hydroxyurea, azacitidine and gemtuzumab 
ozogamicin therapy in patients with previously untreated non-M3 acute myeloid 
leukemia and high-risk myelodysplastic syndromes in the elderly: results from a 
pilot trial. Leuk Lymphoma 2008;49(11):2141-7. 
182.Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, 
Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, 
Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, 
Amadori S and Leone G. Valproic acid at therapeutic plasma levels may 
increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin 
Cancer Res 2009;15(15):5002-7. 
183.Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S and Galili N. Combination of 5-
azacytidine and thalidomide for the treatment of myelodysplastic syndromes 
and acute myeloid leukemia. Cancer 2008;113(7):1596-604. 
184.Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda 
WG, Ousounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM and 
Garcia-Manero G. Safety and clinical activity of the combination of 5-
azacytidine, valroic acid, and all-trans retinoic acid in acute myeloid leukemia 
and myelodysplastic syndrome. Blood 2007;110(7):2302-8. 
185.Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell 
P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen 
JM, Wallvik J, Öberg G, Hokland P, Jacobsen SE, Porwit A and Hellström-
Lindberg E. Maintenance treatment with azacytidine for patients with high-risk 
myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS in 
complete remission after induction chemotherapy. Br J Haematol 
2010;150(3):293-302. 
186.Thépot S, Itzykson R, Seegers V, Recher C, Quesnel B, Delaunay J, Cluzeau 
T, Koka AM, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Salanoubat C, 
Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Wattel E, Isnard F, 
Sanhes L, Harel S, de Botton S, Chait Y, Uzunov M, Guerci A, Dahoun M, Vey 
N, Dombret H, Dreyfus F, Ades L, Fenaux P and Gardin C. Azacytidine (AZA) 
 68
 as first line therapy in AML: results of the frensh ATU program. Blood (Annual 
Meeting Abstracts) 2009;114:843. 
187.Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in 
subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 
1994;84(1):339-43. 
188.Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R. FDA approval 
summary: vorinostat for treatment of advanced primary cutaneous t-cell 
lymphoma. Oncologist 2007;12(10):1247-52. 
189.Finnin MS, Donigian JR, Cohen A,Richon VM, Rifkind RA, Marks PA, Breslow 
R and Pevletich NP. Structures of a histone deacetylase homologue bound to 
the TSA and SAHA inhibitors. Nature 1999;401(6749):188-93. 
190.Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T and 
Sanders K. Distinct pharmacological properties of second generation HDAC 
inhibitors with the benzamide or hydroxamate head group. Int J Cancer 
2007;121(5):1138-48. 
191.Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone 
deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84. 
192.Keundgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, 
Germing U and Gattermann N. Treatment of myelodysplastic syndromes with 
valproic alone or in combination with all-trans retinoic acid. Blood 
2004;104(5):1266-9. 
193.Keundgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing 
U, Haas R, Döhner H and Gattermann N. The histone deacetylase (HDAC) 
inhibitor valproic acid as monotherapy or in combination with all-trans retinoic 
acid in patients with acute myeloid leukemia. Cancer 2006;106(1):112-9. 
194.Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Scharz K, Romanski A, 
Kramer OH, Kampfmann M, Hoetzer D, Neubauer A, Ruthhardt M and Ottmann 
OG. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-
risk acute myeloid leukemia. Cancer 2005;104(12):2717-25. 
195.Cimino G, Lo-Coco, F, Fenu S,Travaglini L, Finolezzi E, Mancini M, Nanni M, 
Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori 
S, Mandelli F, Pelicci PG and Nervi C. Sequential valproic acid/all-trans retinoic 
acid treatment reprograms differentiation in refractory and high-risk acute 
meyloid leukemia. Cancer Res 2006;66(17):8903-11 
196.Craddock C, Bradbury C, Narayanan S, Rye A, Basu Supratik, MacWhannell 
A, Sawers A, Cook M, Griffiths M, Grimwade D, Bunce C and Turner B. 
Predictors of clinical response in patients with high risk acute myeloid leukemia 
receiving treatment with the histone deacetylase inhibitor sodium valproate. 
Blood (ASH Annual Meeting Abstracts) 2005;106;2791. 
197.Garcia-Manero G, Kantarjian HM, Sanchez-González B, Yang H, Rosner G, 
Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, 
Estrov Z, Cortes J, O’Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour 
E and Issa JP. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine 
with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9 
198.Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, 
Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, 
 69
 Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR 
and Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat 
(suberoylanilide hydroxamic acid [SAHA] in patients with advanced leukemias 
and myelodysplastic syndromes. Blood 2008;111(3):1060-6. 
199.Kirschbaum M, Gojo I, Goldberg SL, Kujawski L, Atallah E, Marks P, Garcia-
Vargas J, Rizvi S, di Gravio D, Ahern J and Issa JP. Phase I study of vorinostat 
in combination with decitabine in patients with replapsed or newly diagnosed 
acute myelogeneus leukemia or myelodysplastic syndromes. Blood (ASH 
Annual Meeting Abstracts) 2008;112:1564. 
200.Silverman LR, Verma A, Odichmar-Reissig R, LeBlanc A, Najfeld V, Gabrilove 
J, Isola L, Espinoza-Delgdo I and Zwiebel J. A phase I trial of the epigenetic 
modulators vorinostat, in combination with azacitidine (azaC) in patients with 
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study 
of the New York Cancer Consortium. Blood (ASH Annual Meeting Abstracts) 
2008;112:3656. 
201.Liest M, Single B, Castoldi AF, Kühnle S and Nicotera P. Intracellular 
adenosine triphospate (ATP) concentration: a switch in the dicision between 
apoptosis and nectrosis. J Exp Med 1997;185(8):1481-6. 
202.Jacobson MD, Weil M and Raff MC. Programmed cell death in animal 
development. Cell 1997:88(3):347-54. 
203.Kerr JF, Wyllie AH and Currie AR. Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26(4):239-57. 
204.Hengartner MO. The biochemistry of apoptosis. Nature 2000;407(6805):770-6. 
205.Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-
70. 
206.Junttila MR and Evan GI. P53 – a Jack of all trades but master of none. Nat 
Rev Cancer 2009;9(11):821-9. 
207.Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in 
hematologic malignancies. Semin Hematol 1997;34 Suppl 5:S9-19. 
208.Zeschnik M, LLich C, Buiting K, Doerfler W and Horsthemke B. A single-tube 
PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on 
allelic methylation differences at the SNRPN locus. Eur J Hum Genet 
1997;5(2):94(8). 
209.Cremonesi L, Firpo S, Ferrari M, Righetti PG and Gelfi C. Double-gradient 
DGGE for optimized detection of DNA point mutations. Biotechniques 
1997;22(2):326-30. 
210.Guldberg P, Worm J and Grønbæk K. Profiling DNA methylation by melting 
analysis. Methods 2002;27(2):121-7. 
211.Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, 
Tannir N, Horne E, Groshen S, Jones P, Yang A and Issa JP. LINE-1 
methylation in plasma DNA as a biomarker of activity of DNA methylation 
inhibitors in patients with solid tumors. Epigenetics 2009;4(3):176-84. 
212.Karimi M, Johansson S and Ekström TJ. Using LUMA: a Luminometric-based 
assay for global DNA-methylation. Epigenetics 2006;1(1):45-8. 
 70
 213.Fan JB, Gunderson KL, Bibikova M, Yeakley JM, Chen J, Wickham Garcia E, 
Lebruska LL, Laurent M, Shen R and Barker D. Illumina universal bead arrays. 
Methods Enzymol 2006;410;57-73. 
214.Riccardi C and Nicoletti I. Analysis of apoptosis by propidium iodide staining 
and flow cytometry. Nat Protoc 2006;1(3):1458-61. 
215.Andersson JE, Kopecky KJ, Willman CL, Head D, O’Donnell MR, LUthardt FW, 
Norwood TH, Chen IM, Balcerzak SP, Johnson DB and Appelbaum FR. 
Outcome after induction chemotherapy for older patients with acute myeloid 
leukemia is not improved with mitoxantrone and etoposide compared to 
cytarabine and daunorubicin: a Southwest Oncology Group Study. Blood 
2002;100(12):3869-76. 
216.Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, 
Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal 
M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdock LF, Beck J, Döhner 
H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for 
Hemato-Oncology (HOVON); German AML Study Group AMLSG; Swiss Group 
for Clinical Cancer Research (SAKK) Collaborative Group. High-dose 
daunorubicine in older patients with acute myeloid leukemia. N Engl J Med 
2009;361(13):1235-48. 
217.Hellström-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, 
Fadeel B and Zhivotovsky B. Apoptosis in refractory anemia with ringed 
sideroblasts is initiated at the stem cell level and associated with increased 
activation of caspases. Br J Haematol 2001;112(3):714-26. 
 
 
 
 
 
 
 
 
 
 
 
 71
 11 STUDY I‐IV 
 72
